2022

HIV SURVEILLANCE SUMMARY REPORT, GEORGIA





The **2022 HIV Surveillance Summary, Georgia** is published by the Georgia Department of Public Health (DPH), Division of Epidemiology, HIV Epidemiology Section, 200 Piedmont Avenue SE, West Tower Floor 10, Atlanta, GA 30334. Data are presented from known diagnoses and laboratory reports entered into the Georgia Enhanced HIV/AIDS Reporting System (eHARS). All data are provisional.

The *HIV Surveillance Summary, Georgia 2022* is not copyrighted and may be used and reproduced without permission. Citation of the source is, however, appreciated.

SUGGESTED CITATION: Georgia Department of Public Health, HIV Epidemiology Section, 2022 HIV Surveillance Summary, Georgia, https://dph.georgia.gov/epidemiology/georgias-hivaids-epidemiology-section/hivaids-case-surveillance, Published March 2024, [Accessed: date]

ACKNOWLEDGEMENTS: Publication of this report was made possible with the contributions of the Georgia DPH HIV Epidemiology Section's Core HIV Surveillance staff, HIV Case Report Forms submitted by Georgia healthcare facility staff, HIV infection-related laboratory test results transmitted by laboratory facilities in Georgia, data matches with other DPH programs, and the ongoing efforts of multiple individuals from public and private sector organizations dedicated to improving surveillance, prevention, testing, and care of people with HIV infection.

This report was prepared by the following staff from the Georgia Department of Public Health: Nellie Garlow, MPH; Jose Adame, MPH; Jenna Gettings, DVM, MPH; Cherie Drenzek, DVM, MS. Please direct all inquiries to Dr. Jenna Gettings (Jenna.Gettings@dph.ga.gov).

Georgia HIV Core Surveillance Team contributors: Lauren Barrineau-Vejjajiva, Thelma Fannin, LaTosha Johnson, LaToya Lemons, Daniel Mauck, Mildred McGainey, Contessa Meadows, Kim Norris, Rama Namballa, Doris Pearson, Courtney Philpot, A. Eugene Pennisi, Sylve Rawls, Akilah Spratling, and Gerrianna Williams.

TABLE OF CONTENTS

Int	roduction	5
Technical Notes Definitions References Tables HIV Diagnoses and People with HIV, Georgia Table 1. HIV Diagnoses, Late Diagnoses, and Stage 3 (AIDS) Diagnoses, Georgia, 2022 Table 2. HIV Diagnoses, Late Diagnoses, and Stage 3 (AIDS) Diagnoses among Cisgender Males, Georgia, 2022 Table 3. HIV Diagnoses, Late Diagnoses, and Stage 3 (AIDS) Diagnoses among Cisgender Females, Georgia, 2022 Table 4. HIV Diagnoses, Late Diagnoses, and Stage 3 (AIDS) Diagnoses among Cisgender Females, Georgia, 2022 Table 5. People with HIV (PWH) and PWH Ever Stage 3 (AIDS), Georgia, 2022 Table 6. People with HIV (PWH) and PWH Ever Stage 3 (AIDS), Cisgender Males, Georgia, 2022 Table 7. People with HIV (PWH) and PWH Ever Stage 3 (AIDS), Cisgender Females, Georgia, 2022 Table 8. People with HIV (PWH) and PWH Ever Stage 3 (AIDS), Transgender Persons and Persons with an Addition Gender Identity, Georgia, 2022 HIV Diagnoses and People with HIV by Public Health District Table 9. HIV Diagnoses and People with HIV (PWH), District 1-1 (Rome), Georgia, 2022 Table 10. HIV Diagnoses and People with HIV, District 1-2 (Dalton), Georgia, 2022 Table 11. HIV Diagnoses and People with HIV, District 3-1 (Cobb/Douglas), Georgia, 2022 Table 13. HIV Diagnoses and People with HIV, District 3-1 (Cobb/Douglas), Georgia, 2022	6	
Def	Definitions IV Diagnoses and People with HIV, Georgia Table 1. HIV Diagnoses, Late Diagnoses, and Stage 3 (AIDS) Diagnoses, Georgia, 2022 Table 2. HIV Diagnoses, Late Diagnoses, and Stage 3 (AIDS) Diagnoses among Cisgender Males, Georgia, 2022 Table 3. HIV Diagnoses, Late Diagnoses, and Stage 3 (AIDS) Diagnoses among Cisgender Females, Georgia, 2022 Table 4. HIV Diagnoses, Late Diagnoses, and Stage 3 (AIDS) Diagnoses among Transgender Persons and Persons wi an Additional Gender Identity, Georgia, 2022 Table 5. People with HIV (PWH) and PWH Ever Stage 3 (AIDS), Georgia, 2022 Table 6. People with HIV (PWH) and PWH Ever Stage 3 (AIDS), Cisgender Males, Georgia, 2022 Table 7. People with HIV (PWH) and PWH Ever Stage 3 (AIDS), Cisgender Females, Georgia, 2022 Table 8. People with HIV (PWH) and PWH Ever Stage 3 (AIDS), Transgender Persons and Persons with an Additional Gender Identity, Georgia, 2022 IV Diagnoses and People with HIV by Public Health District Table 9. HIV Diagnoses and People with HIV (PWH), District 1-1 (Rome), Georgia, 2022 Table 10. HIV Diagnoses and People with HIV, District 1-2 (Dalton), Georgia, 2022 Table 11. HIV Diagnoses and People with HIV. District 2 (Gainesville), Georgia, 2022	8
References Tables HIV Diagnoses and People with HIV, Georgia	9	
	10	
ΗI\	/ Diagnoses and People with HIV, Georgia	11
	Table 1. HIV Diagnoses, Late Diagnoses, and Stage 3 (AIDS) Diagnoses, Georgia, 2022	11
	Table 2. HIV Diagnoses, Late Diagnoses, and Stage 3 (AIDS) Diagnoses among Cisgender Males, Georgia, 2022	12
	Table 3. HIV Diagnoses, Late Diagnoses, and Stage 3 (AIDS) Diagnoses among Cisgender Females, Georgia, 2022	13
	Table 5. People with HIV (PWH) and PWH Ever Stage 3 (AIDS), Georgia, 2022	15
	Table 6. People with HIV (PWH) and PWH Ever Stage 3 (AIDS), Cisgender Males, Georgia, 2022	16
	Table 7. People with HIV (PWH) and PWH Ever Stage 3 (AIDS), Cisgender Females, Georgia, 2022	17
ΗI\	/ Diagnoses and People with HIV by Public Health District	19
	Table 9. HIV Diagnoses and People with HIV (PWH), District 1-1 (Rome), Georgia, 2022	19
	Table 10. HIV Diagnoses and People with HIV, District 1-2 (Dalton), Georgia, 2022	20
	Table 11. HIV Diagnoses and People with HIV, District 2 (Gainesville), Georgia, 2022	21
	Table 12. HIV Diagnoses and People with HIV, District 3-1 (Cobb/Douglas), Georgia, 2022	22
	Table 13. HIV Diagnoses and People with HIV, District 3-2 (Fulton), Georgia, 2022	23
	Table 14. HIV Diagnoses and People with HIV, District 3-3 (Clayton), Georgia, 2022	24
	Table 15. HIV Diagnoses and People with HIV, District 3-4 (East Metro), Georgia, 2022	25
	Table 16. HIV Diagnoses and People with HIV, District 3-5 (DeKalb), Georgia, 2022	26
	Table 17. HIV Diagnoses and People with HIV, District 4 (LaGrange), Georgia, 2022	27
	Table 18. HIV Diagnoses and People with HIV, District 5-1 (Dublin), Georgia, 2022	28
	Table 19. HIV Diagnoses and People with HIV, District 5-2 (Macon), Georgia, 2022	29

	Table 20. HIV Diagnoses and People with HIV, District 6 (Augusta), Georgia, 2022
	Table 21. HIV Diagnoses and People with HIV, District 7 (Columbus), Georgia, 2022
	Table 22. HIV Diagnoses and People with HIV, District 8-1 (Valdosta), Georgia, 2022
	Table 23. HIV Diagnoses and People with HIV, District 8-2 (Albany), Georgia, 2022
	Table 24. HIV Diagnoses and People with HIV, District 9-1 (Savannah), Georgia, 2022
	Table 25. HIV Diagnoses and People with HIV, District 9-2 (Waycross), Georgia, 202235
	Table 26. HIV Diagnoses and People with HIV, District 10 (Athens), Georgia, 202236
HIV	Diagnoses and People with HIV, Atlanta MSA37
	Table 27. HIV Diagnoses and People with HIV, Atlanta Metropolitan Statistical Area (MSA) ¹ , Georgia, 202237
нιν	Diagnoses and Late Diagnoses by Public Health District and Atlanta MSA38
	Table 28. HIV Diagnoses and Late Diagnoses by Public Health District and Atlanta Metropolitan Statistical Area (MSA), Georgia, 2022
Puk	olic Health District and County Rates39
	Table 29. HIV Diagnoses and People with HIV (PWH) by Public Health District and County (number and rates per 100,000 population), Georgia, 2022
Dea	oths among People with HIV43
	Table 30. Deaths among People with HIV (PWH), Georgia 2022
Dis	tribution of General Population by Race/Ethnicity44
	Table 31. Distribution of the General Population by Race/Ethnicity, Georgia, 202244
Sup	pplementary Information45
	Additional Data on HIV in Georgia
	Reporting
	Requesting Data45

INTRODUCTION

HIV remains an important public health topic in the state of Georgia. As of the end of 2022, there were 63,984 people with HIV in Georgia, and 2,575 people were diagnosed in 2022. The number of people living with HIV continues to increase because of effective therapies now available, allowing people with HIV, who are diagnosed early and treated, to have long and health lives¹. Based on the Centers for Disease Control and Prevention's 2021 HIV Surveillance Report, Georgia was ranked the 4th highest in the nation for the total number of new diagnoses of HIV infection among adults and adolescents after California, Texas, and Florida, and ranked the 5th highest for the number of people with HIV infection, after California, New York, Florida, and Texas². Georgia ranked 2nd in the rate of HIV diagnosis among adults and adolescents after the District of Columbia, and 3rd in the rate of people with HIV after the District of Columbia and New York.

Monitoring the HIV epidemic in Georgia is essential for meeting the goals stated in the 2022-2025 National HIV/AIDS Strategy to: 1) prevent new HIV infections; 2) improve HIV-related health outcomes for people with HIV; 3) reduce HIV-related health disparities and inequities, and 4) achieve a more coordinated national response to the HIV epidemic among all partners and stakeholders³.

Information on the Georgia HIV care continuum can be found in a separate report at the following web page: https://dph.georgia.gov/epidemiology/georgias-hivaids-epidemiology-section/hiv-care-continuum.

After the COVID-19 pandemic was declared a national and state emergency in March 2020, access to healthcare services, including HIV testing, prevention, and care-related services, became reduced or temporarily suspended. The number of people diagnosed with HIV decreased in 2020, at least in part because of decreased testing availability and changes in health care seeking patterns but returned to pre-COVID-19 levels in 2021.

TECHNICAL NOTES

Georgia statutes and regulations (O.C.G.A. §31-12-2(b)) require healthcare providers (such as nurses, nurse practitioners, doctors, physician assistants) licensed in the state of Georgia to report all cases of HIV infection and/or Stage 3 (AIDS) to the Georgia DPH within seven days of diagnosis⁴. Laboratories licensed in the state of Georgia are required to report all HIV-related laboratory test results within 7 days. The information is used to monitor the HIV epidemic in Georgia and guide program planning and evaluation. The data presented in the accompanying tables are based on confidential case reports collected through the Georgia DPH enhanced HIV/AIDS Reporting System (eHARS).

AIDS reporting began in the early 1980s, and HIV reporting began in Georgia on December 31, 2003. Electronic transmission of laboratory test results began in 2011. Receipt of CD4 counts and viral load tests make it possible to estimate the HIV Care Continuum for people with a diagnosis of HIV infection in the state of Georgia (reports are available at: https://dph.georgia.gov/epidemiology/georgias-hivaids-epidemiology-section/hiv-care-continuum.

This report includes surveillance data reported through December 31, 2023 for cases diagnosed through December 31, 2022. This report is limited to cases diagnosed through December 2022 to take into account delays in reporting, and to allow for obtaining follow up information on reported cases.

HIV diagnoses include people with a diagnosis of HIV infection, regardless of the stage of disease at diagnosis, who were residents of Georgia at the time of diagnosis. People with HIV are those with a residence in the state of Georgia during the given year, based on current information available in the Georgia HIV surveillance system, regardless of where they resided at the time of diagnosis. People residing in correctional facilities are included in this report and may inflate rates in certain geographic regions where there are large numbers of HIV-positive inmates.

Information on HIV transmission category is missing for approximately one quarter of cases. Multiple imputation, a statistical approach, is used to replace each missing transmission category with a set of plausible values that represent the uncertainty about the true, but missing, value⁵. The methods were applied to adult and adolescent, but not pediatric, cases. Multiple imputation is considered by the Centers for Disease Control and Prevention (CDC) to be the best method for redistribution of missing data in large databases. HIV transmission category is shown with missing data, and after multiple imputation. Cases missing race/ethnicity are not assigned a transmission category through multiple imputation. For more information, see the CDC's technical notes on multiple imputation: https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/content/technical-notes.html.

Prior to 2021, gender identity was determined based on sex assigned at birth and current gender identity (i.e., most recent data available). In 2021, the calculation for gender identity was adjusted by adding information from a third variable: whether the patient had <u>ever</u> had "transgender – female to male", "transgender – male to female", or "additional gender identity" listed as their current gender identity in their eHARS record. This was added to account

for potential documentation issues, such as if a more recent case report form was incomplete and did not include updated information on a person's transgender or additional gender identity status. As a result of this change, ascertainment increased of people whose gender identity was transgender or additional gender identity. For instance, in 2020, there were 683 transgender individuals living with HIV and in 2021, there were 893 transgender individuals and 39 individuals with an additional gender identity living with HIV.

Current gender identity is sometimes incomplete in eHARS records, so the numbers reported in these summary tables for transgender and additional gender identity are most likely an underestimate. Current gender identity fields which include the options of "transgender – female to male" and "transgender – male to female" were added to the case report form in 2007, thus prevalent counts of HIV among transgender people may be incomplete among people diagnosed prior to 2007.

People with a transmission category of "perinatal/other pediatric" include infants born in Georgia who had an HIV infection that was likely attributed to perinatal transmission, as well as infants born outside of Georgia who had an HIV infection that was likely attributed to perinatal transmission and were first diagnosed with HIV in Georgia. For more information on perinatal HIV exposure surveillance in Georgia, see the Perinatal HIV Exposure Surveillance Report at https://dph.georgia.gov/epidemiology/georgias-hivaids-epidemiology-section/perinatal-exposure-surveillance.

For data presented at the Public Health District or Atlanta Metropolitan Statistical Area (MSA) level, all cells with values between 1 and 4 observations are censored in accordance with the Georgia Department of Public Health HIV Surveillance Security and Confidentiality Guidelines.

DEFINITIONS

HIV DIAGNOSES are cases diagnosed between January 1 and December 31, 2022, with a Georgia address of residence at the time of HIV diagnosis, and who were reported to the Georgia Department of Public Health by December 31, 2023, regardless of stage at diagnosis. This group includes people whose initial diagnosis is Stage 3 (AIDS).

LATE DIAGNOSES are the subset of HIV diagnoses who are found to be Stage 3 (AIDS) within 12 months of HIV diagnosis date. Such instances are termed late diagnoses because of the advanced stage at diagnosis indicates that the person was most likely infected for many years before diagnosis.

STAGE 3 (AIDS) DIAGNOSES include two groups: 1) people newly diagnosed with HIV in 2022, found to meet the definition for Stage 3 (AIDS) at diagnosis, and with a Georgia address at or near the time of Stage 3 diagnosis; and 2) people found to meet the Stage 3 definition in 2022 with a Georgia address at or near the time of Stage 3 diagnosis, regardless of the date of their initial HIV diagnosis.

PEOPLE WITH HIV INFECTION are people diagnosed by December 31, 2022, who are not known to be deceased, and for whom the most recent address available is in Georgia.

PEOPLE WITH HIV, EVER STAGE 3 are people diagnosed by December 31, 2022, who are not known to be deceased, for whom the most recent address available is in Georgia, and who met the case definition for Stage 3 (AIDS) at some point.

TRANSMISSION CATEGORIES presented in this report follow the standards created by the Centers for Disease Control and Prevention (CDC) and have been used for many years. HIV Transmission categories are associated with a case using a classification system that is based on the likelihood that an HIV infection may be attributed to one or more types of exposures. The summary classification results from selecting the one most likely factor to be attributed to the HIV infection from the presumed hierarchical order of probability. For surveillance purposes, HIV and AIDS cases are counted only once in the hierarchy of transmission categories. People with more than one reported factor that can likely be attributed to the HIV infection are classified in the transmission category according to the exposure that is most likely to have resulted in transmission. The exception is men who report sexual contact with other men and injection drug use; this group makes up a separate transmission category. Individuals indicated as having "No risk identified or reported (NIR/NRR)" did not have any likely modes of exposure to HIV indicated in their case investigation.

CURRENT RESIDENCE Current address is determined using the date of the most recently entered residential address as of 12/31/2022 into eHARS. The number of people with HIV is based on current address.

VITAL STATUS: People are assumed to be alive unless otherwise documented or reported. The Georgia DPH performs an annual match of the eHARS database with the Georgia Vital Records death data, the National Death Index, and the Social Security Death Index to ascertain vital status.

RATES: Denominators for population rates are based on the 2022 estimates of the Georgia resident population retrieved from the Georgia Department of Public Health, Office of Health Indicators for Planning (OHIP).

PERCENTAGES: Total percentages may not add up to 100% due to rounding.

COUNTS: Counts in the gender, race/ethnicity, and age categories may not add up to the overall totals due to a small number of cases with missing information (<2 percent).

REFERENCES

- 1. Trickey, Adam et al. "Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies." *The lancet. HIV* vol. 10,5 (2023): e295-e307. doi:10.1016/S2352-3018(23)00028-0
- 2. Centers for Disease Control and Prevention. *HIV Surveillance Report, 2021*. https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-34/index.html. Published May 2023.
- 3. White House Office of National AIDS Policy. *National HIV/AIDS Strategy (2022-2025)*. https://hivgov-prod-v3.s3.amazonaws.com/s3fs-public/NHAS-2022-2025.pdf. Published 2021.
- 4. Department of Public Health, Rules and regulations 290-48.11 (2003); Official Code of Georgia Annotated (O.C.G.A.) § 31-22-9.2 (2011)
- 5. Harrison KM, Kajese T, Hall HI, Song R. Risk factor redistribution of the national HIV/AIDS surveillance data: an alternative approach. Public Health Rep 2008;123:618–27.

TABLES

HIV DIAGNOSES AND PEOPLE WITH HIV, GEORGIA

TABLE 1. HIV DIAGNOSES, LATE DIAGNOSES, AND STAGE 3 (AIDS) DIAGNOSES, GEORGIA, 2022

	HIV Diag (all sta		Late H	IIV Diagnos	es ¹	Stage 3 (Diagno	
	N	%*	N	%*	Row %	N	%*
Total	2,575	100.0	592	100.0	23.0	1,156	100.0
Gender Identity							
Cisgender Male	2,011	78.1	444	75.0	22.1	862	74.6
Cisgender Female	512	19.9	137	23.1	26.8	273	23.6
Transgender Persons/Additional Gender Identity	52	2.0	11	1.9	21.2	21	1.8
Race/Ethnicity							
Black or African American/non-Hispanic	1,726	67.0	391	66.1	22.7	794	68.7
White/non-Hispanic	392	15.2	91	15.4	23.2	170	14.7
Hispanic/Latino, Any Race	347	13.5	90	15.2	25.9	131	11.3
Asian	19	0.7	4	0.7	21.1	9	0.8
American Indian/Alaska Native	3	0.1	0	0.0	0.0	0	0.0
Native Hawaiian/Pacific Islander	0	0.0	0	0.0	0.0	0	0.0
Multiple Races	57	2.2	13	2.2	22.8	44	3.8
Age Group at Diagnosis (Years)							
<13	4	0.2	1	0.2	25.0	3	0.3
13-19	131	5.1	18	3.0	13.7	22	1.9
20-29	960	37.3	155	26.2	16.1	232	20.1
30-39	730	28.4	165	27.9	22.6	398	34.4
40-49	345	13.4	109	18.4	31.6	200	17.3
50-59	265	10.3	105	17.7	39.6	195	16.9
60+	140	5.4	39	6.6	27.9	106	9.2
HIV Transmission Category (Unadjusted)							
Male-to-male sexual contact	1,429	55.5	286	48.3	20.0	558	48.3
Heterosexual contact ³	560	21.8	172	29.1	30.7	273	23.6
Injection drug use	42	1.6	9	1.5	21.4	28	2.4
Male-to-male sexual contact and injection drug	38	1.5	6	1.0	15.8	24	2.1
use							
Adult Other	2	0.1	0	0.0	0.0	0	0.0
Perinatal/other pediatric ⁴	3	0.1	1	0.2	33.3	7	0.6
No risk identified or reported (NIR/NRR)	501	19.5	118	19.9	23.6	266	23.0
HIV Transmission Category (Adjusted) ⁵							
Male-to-male sexual contact	1,710	66.4	347	58.7	20.3	688	59.5
Heterosexual contact ³	715	27.8	215	36.4	30.1	372	32.2
Injection drug use	65	2.5	16	2.6	24.6	43	3.7
Male-to-male sexual contact and injection drug	50	2.0	10	1.7	20.0	32	2.8
use							
Adult Other	2	0.1	0	0.0	0.0	0	0.0
Perinatal/other pediatric ⁴	3	0.1	1	0.2	33.3	7	0.6
No risk identified or reported (NIR/NRR)	30	1.2	3	0.5	10.0	14	1.2

^{*}Percentages may not add up to 100% due to rounding and missing data. 1. Late diagnosis: stage 3 (AIDS) diagnosis within 12 months of HIV diagnosis. Row % is percent of HIV diagnoses that were late diagnoses 2. Stage 3 (AIDS): includes persons diagnosed with stage 3 in 2022, regardless of year of HIV diagnosis. 3. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 4. Perinatal/other pediatric: cases <13 years born to a mother who is HIV-positive, cases <13 with missing risk, and cases <13 with other risk (e.g., sexual transmission). 5. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 2. HIV DIAGNOSES, LATE DIAGNOSES, AND STAGE 3 (AIDS) DIAGNOSES AMONG CISGENDER MALES, GEORGIA, 2022

	HIV Diag		Late I	HIV Diagnos	es¹	Stage 3 (Diagno	-
	N	%*	N	%*	Row %	N	%*
Total	2,011	100.0	444	100.0	22.1	862	100.0
Race/Ethnicity							
Black or African American/non-Hispanic	1,311	65.2	282	63.5	21.5	575	66.7
White/non-Hispanic	308	15.3	68	15.3	22.1	129	15.0
Hispanic/Latino, Any Race	302	15.0	78	17.6	25.8	110	12.8
Asian	18	0.9	4	0.9	22.2	7	0.8
American Indian/Alaska Native	3	0.2	0	0.0	0.0	0	0.0
Native Hawaiian/Pacific Islander	0	0.0	0	0.0	0.0	0	0.0
Multiple Races	47	2.3	9	2.0	19.1	35	4.1
Age Group at Diagnosis (Years)							
<13	2	0.1	0	0.0	0.0	0	0.0
13-19	108	5.4	17	3.8	15.7	18	2.1
20-29	810	40.3	129	29.1	15.9	192	22.3
30-39	591	29.4	137	30.9	23.2	313	36.3
40-49	245	12.2	72	16.2	29.4	134	15.6
50-59	166	8.3	66	14.9	39.8	132	15.3
60+	89	4.4	23	5.2	25.8	73	8.5
HIV Transmission Category (Unadjusted)							
Male-to-male sexual contact	1,382	68.7	277	62.4	20.0	539	62.5
Heterosexual contact ³	185	9.2	66	14.9	35.7	97	11.3
Injection drug use	31	1.5	6	1.4	19.4	16	1.9
Male-to-male sexual contact and injection drug	37	1.8	6	1.4	16.2	24	2.8
use							
Adult Other	1	0.1	0	0.0	0.0	0	0.0
Perinatal/other pediatric ⁴	2	0.1	0	0.0	0.0	2	0.2
No risk identified or reported (NIR/NRR)	373	18.6	89	20.1	23.9	184	21.4
HIV Transmission Category (Adjusted) ⁵							
Male-to-male sexual contact	1,662	82.7	338	76.2	20.3	669	77.6
Heterosexual contact ³	232	11.6	83	18.7	35.8	126	14.6
Injection drug use	43	2.2	10	2.2	23.3	23	2.7
Male-to-male sexual contact and injection drug	49	2.5	10	2.2	20.4	32	3.7
use							
Adult Other	1	0.1	0	0.0	0.0	0	0.0
Perinatal/other pediatric ⁴	2	0.1	0	0.0	0.0	2	0.2
No risk identified or reported (NIR/NRR)	21	1.0	3	0.7	14.3	10	1.2

^{*}Percentages may not add up to 100% due to rounding and missing data. 1. Late diagnosis: stage 3 (AIDS) diagnosis within 12 months of HIV diagnosis. Row % is percent of HIV diagnoses that were late diagnoses 2. Stage 3 (AIDS): includes persons diagnosed with stage 3 in 2022, regardless of year of HIV diagnosis. 3. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 4. Perinatal/other pediatric: cases <13 years born to a mother who is HIV-positive, cases <13 with missing risk, and cases <13 with other risk (e.g., sexual transmission). 5. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 3. HIV DIAGNOSES, LATE DIAGNOSES, AND STAGE 3 (AIDS) DIAGNOSES AMONG CISGENDER FEMALES, GEORGIA, 2022

	HIV Diagnoses (all stages) Late HIV Diagnoses ¹		Stage 3 (AIDS) Diagnoses ²				
	N	%*	N	%*	Row %	N	%*
Total	512	100.0	137	100.0	26.8	273	100.0
Race/Ethnicity							
Black or African American/non-Hispanic	377	73.6	101	73.7	26.8	203	74.4
White/non-Hispanic	81	15.8	21	15.3	25.9	38	13.9
Hispanic/Latino, Any Race	36	7.0	11	8.0	30.6	19	7.0
Asian	1	0.2	0	0.0	0.0	2	0.7
American Indian/Alaska Native	0	0.0	0	0.0	0.0	0	0.0
Native Hawaiian/Pacific Islander	0	0.0	0	0.0	0.0	0	0.0
Multiple Races	8	1.6	4	2.9	50.0	9	3.3
Age Group at Diagnosis (Years)							
<13	2	0.4	1	0.7	50.0	3	1.1
13-19	17	3.3	1	0.7	5.9	4	1.5
20-29	122	23.8	21	15.3	17.2	32	11.7
30-39	125	24.4	24	17.5	19.2	75	27.5
40-49	97	19.0	36	26.3	37.1	65	23.8
50-59	98	19.1	38	27.7	38.8	61	22.3
60+	51	10.0	16	11.7	31.4	33	12.1
HIV Transmission Category (Unadjusted)							
Heterosexual contact ³	373	72.9	105	76.6	28.2	175	64.1
Injection drug use	11	2.2	3	2.2	27.3	12	4.4
Adult Other	1	0.2	0	0.0	0.0	0	0.0
Perinatal/other pediatric ⁴	1	0.2	1	0.7	100.0	5	1.8
No risk identified or reported (NIR/NRR)	126	24.6	28	20.4	22.2	81	29.7
HIV Transmission Category (Adjusted) ⁵							
Heterosexual contact ³	480	93.7	130	95.0	27.1	244	89.4
Injection drug use	21	4.2	6	4.2	28.6	20	7.3
Adult Other	1	0.2	0	0.0	0.0	0	0.0
Perinatal/other pediatric ⁴	1	0.2	1	0.7	100.0	5	1.8
No risk identified or reported (NIR/NRR)	9	1.8	0	0.0	0.0	4	1.5

^{*}Percentages may not add up to 100% due to rounding and missing data. 1. Late diagnosis: stage 3 (AIDS) diagnosis within 12 months of HIV diagnosis. Row % is percent of HIV diagnoses that were late diagnoses 2. Stage 3 (AIDS): includes persons diagnosed with stage 3 in 2022, regardless of year of HIV diagnosis. 3. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 4. Perinatal/other pediatric: cases <13 years born to a mother who is HIV-positive, cases <13 with missing risk, and cases <13 with other risk (e.g., sexual transmission). 5. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 4. HIV DIAGNOSES, LATE DIAGNOSES, AND STAGE 3 (AIDS) DIAGNOSES AMONG TRANSGENDER PERSONS AND PERSONS WITH AN ADDITIONAL GENDER IDENTITY, GEORGIA, 2022

	HIV Diag (all stag		Late I	HIV Diagnos	es¹	Stage 3 (Diagno	
	N	%*	N	%*	Row %	N	%*
Total	52	100.0	11	100.0	21.2	21	100.0
Gender Identity							
Transgender Woman	47	90.4	8	72.7	17.0	18	85.7
Transgender Man	2	3.9	1	9.1	50.0	1	4.8
Additional Gender Identity	3	5.8	2	18.2	66.7	2	9.5
Race/Ethnicity							
Black or African American/non-Hispanic	38	73.1	8	72.7	21.1	16	76.2
White/non-Hispanic	3	5.8	2	18.2	66.7	3	14.3
Hispanic/Latino, Any Race	9	17.3	1	9.1	11.1	2	9.5
Asian	0	0.0	0	0.0	0.0	0	0.0
American Indian/Alaska Native	0	0.0	0	0.0	0.0	0	0.0
Native Hawaiian/Pacific Islander	0	0.0	0	0.0	0.0	0	0.0
Multiple Races	2	3.9	0	0.0	0.0	0	0.0
Age Group at Diagnosis (Years)							
<13	0	0.0	0	0.0	0.0	0	0.0
13-19	6	11.5	0	0.0	0.0	0	0.0
20-29	28	53.9	5	45.5	17.9	8	38.1
30-39	14	26.9	4	36.4	28.6	10	47.6
40-49	3	5.8	1	9.1	33.3	1	4.8
50-59	1	1.9	1	9.1	100.0	2	9.5
60+	0	0.0	0	0.0	0.0	0	0.0
HIV Transmission Category (Unadjusted)							
Sexual contact ³	49	94.2	10	90.9	69.1	20	95.2
Injection drug use	0	0.0	0	0.0	0.0	0	0.0
Sexual contact and injection drug use	1	1.9	0	0.0	0.0	0	0.0
Adult Other	0	0.0	0	0.0	0.0	0	0.0
Perinatal/other pediatric	0	0.0	0	0.0	0.0	0	0.0
No risk identified or reported (NIR/NRR)	2	3.9	1	9.1	50.0	1	4.8
HIV Transmission Category (Adjusted) ⁴							
Sexual contact ³	51	98.1	11	100.0	85.4	21	100.0
Injection drug use	0	0.0	0	0.0	0.0	0	0.0
Sexual contact and injection drug use	1	1.9	0	0.0	0.0	0	0.0
Adult Other	0	0.0	0	0.0	0.0	0	0.0
Perinatal/other pediatric	0	0.0	0	0.0	0.0	0	0.0
No risk identified or reported (NIR/NRR)	0	0.0	0	0.0	0.0		

^{*} Percentages may not add up to 100% due to rounding. 1. Late diagnosis: stage 3 (AIDS) diagnosis within 12 months of HIV diagnosis. 2. Stage 3 (AIDS): includes persons diagnosed with stage 3 in 2022, regardless of year of HIV diagnosis. 3. Includes sex with male and probable heterosexual transmission as noted in medical chart. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 5. PEOPLE WITH HIV (PWH) AND PWH EVER STAGE 3 (AIDS), GEORGIA, 2022

	PWH		Ever Stage 3	(AIDS)1
	N	%*	N	%*
Total	63,984	100.0	31,013	100.0
Gender Identity				
Cisgender Male	48,237	75.4	23,200	74.8
Cisgender Female	14,684	23.0	7,372	23.8
Transgender Persons/Additional Gender Identity	1,010	1.6	430	1.4
Race/Ethnicity				
Black or African American/non-Hispanic	43,317	67.7	21,333	68.8
White/non-Hispanic	10,421	16.3	4,949	16.0
Hispanic/Latino, Any Race	5,412	8.5	2,531	8.2
Asian	332	0.5	119	0.4
American Indian/Alaska Native	25	0.0	11	0.0
Native Hawaiian/Pacific Islander	16	0.0	7	0.0
Multiple Races	3,530	5.5	1,913	6.2
Current Age Group (Years)				
<13	71	0.1	22	0.1
13-19	279	0.4	45	0.2
20-29	6,731	10.5	1,377	4.4
30-39	15,674	24.5	5,605	18.1
40-49	12,948	20.2	6,498	21.0
50-59	15,475	24.2	9,302	30.0
60+	12,795	20.0	8,162	26.3
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	33,625	52.6	15,471	49.9
Heterosexual contact ²	10,809	16.9	5,863	18.9
Injection drug use	2,345	3.7	1,613	5.2
Male-to-male sexual contact and injection drug use	2,085	3.3	1,270	4.1
Adult Other ³	596	0.9	302	1.0
Perinatal/other pediatric ⁴	66	0.1	21	0.1
No risk identified or reported (NIR/NRR)	14,458	22.6	6,473	20.9
HIV Transmission Category (Adjusted) ⁵				
Male-to-male sexual contact	40,119	62.7	18,356	59.2
Heterosexual contact ²	16,353	25.6	8,462	27.3
Injection drug use	3,366	5.3	2,195	7.1
Male-to-male sexual contact and injection drug use	2,550	4.0	1,525	4.9
Adult Other ³	596	0.9	302	1.0
Perinatal/other pediatric ⁴	66	0.1	21	0.1

^{*} Percentages may not add up to 100% due to rounding. 1. Persons whose infection was ever classified as stage 3 (AIDS). 2. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 3. Includes perinatal exposure current age ≥ 13, hemophilia, blood transfusion. 4. Perinatal/other pediatric: cases<13 born to a mother who is HIV-positive, and cases <13 with missing risk. 5. Adjusted for missing risk using multiple imputation methods.

TABLE 6. PEOPLE WITH HIV (PWH) AND PWH EVER STAGE 3 (AIDS), CISGENDER MALES, GEORGIA, 2022

	PWH		Ever Stage 3	(AIDS)1
	N	%*	N	%*
Total	48,237	100.0	23,200	100.0
Race/Ethnicity				
Black or African American/non-Hispanic	31,325	64.9	15,244	65.7
White/non-Hispanic	8,879	18.4	4,255	18.3
Hispanic/Latino, Any Race	4,366	9.1	2,031	8.8
Asian	253	0.5	93	0.4
American Indian/Alaska Native	22	0.1	8	0.0
Native Hawaiian/Pacific Islander	9	0.0	5	0.0
Multiple Races	2,709	5.6	1,451	6.3
Current Age Group (Years)				
<13	29	0.1	10	0.0
13-19	192	0.4	37	0.2
20-29	5,545	11.5	1,094	4.7
30-39	12,788	26.5	4,582	19.8
40-49	9,237	19.2	4,644	20.0
50-59	11,291	23.4	6,827	29.4
60+	9,149	19.0	6,005	25.9
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	32,724	67.8	15,089	65.0
Heterosexual contact ²	2,848	5.9	1,716	7.4
Injection drug use	1,274	2.6	900	3.9
Male-to-male sexual contact and injection drug use	2,042	4.2	1,252	5.4
Adult Other ³	286	0.6	145	0.6
Perinatal/other pediatric ⁴	27	0.1	9	0.0
No risk identified or reported (NIR/NRR)	9,036	18.7	4,089	17.6
HIV Transmission Category (Adjusted) ⁵				
Male-to-male sexual contact	39,207	81.3	17,971	77.5
Heterosexual contact ²	3,849	8.0	2,299	9.9
Injection drug use	1,701	3.5	1,158	5.0
Male-to-male sexual contact and injection drug use	2,506	5.2	1,506	6.5
Adult Other ³	286	0.6	145	0.6
Perinatal/other pediatric ⁴	27	0.1	9	0.0
No risk identified or reported (NIR/NRR)	661	1.4	112	0.5

^{*} Percentages may not add up to 100% due to rounding. 1. Persons whose infection was ever classified as stage 3 (AIDS). 2. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 3. Includes perinatal exposure current age ≥ 13, hemophilia, blood transfusion. 4. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 5. Adjusted for missing risk using multiple imputation methods.

TABLE 7. PEOPLE WITH HIV (PWH) AND PWH EVER STAGE 3 (AIDS), CISGENDER FEMALES, GEORGIA, 2022

	PWH		Ever Stage 3	(AIDS)1
	N	%*	N	%*
Total	14,684	100.0	7,372	100.0
Race/Ethnicity				
Black or African American/non-Hispanic	11,196	76.3	5,751	78.0
White/non-Hispanic	1,493	10.2	677	9.2
Hispanic/Latino, Any Race	933	6.4	449	6.1
Asian	78	0.5	25	0.3
American Indian/Alaska Native	3	0.0	3	0.0
Native Hawaiian/Pacific Islander	6	0.0	1	0.0
Multiple Races	760	5.2	438	5.9
Current Age Group (Years)				
<13	42	0.3	12	0.2
13-19	79	0.5	8	0.1
20-29	948	6.5	226	3.1
30-39	2,443	16.6	848	11.5
40-49	3,513	23.9	1,752	23.8
50-59	4,059	27.6	2,399	32.5
60+	3,595	24.5	2,126	28.8
HIV Transmission Category (Unadjusted)				
Heterosexual contact ²	7,935	54.0	4,133	56.1
Injection drug use	1,066	7.3	710	9.6
Adult Other ³	305	2.1	154	2.1
Perinatal/other pediatric ⁴	39	0.3	12	0.2
No risk identified or reported (NIR/NRR)	5,339	36.4	2,363	32.1
HIV Transmission Category (Adjusted) ⁵				
Heterosexual contact ²	12,463	84.9	6,143	83.3
Injection drug use	1,657	11.3	1,033	14.0
Adult Other ³	305	2.1	154	2.1
Perinatal/other pediatric ⁴	39	0.3	12	0.2
No risk identified or reported (NIR/NRR)	220	1.5	30	0.4

^{*} Percentages may not add up to 100% due to rounding. 1. Persons whose infection was ever classified as stage 3 (AIDS). 2. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 3. Includes perinatal exposure current age \geq 13, hemophilia, blood transfusion. 4. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 5. Adjusted for missing risk using multiple imputation methods.

TABLE 8. PEOPLE WITH HIV (PWH) AND PWH EVER STAGE 3 (AIDS), TRANSGENDER PERSONS AND PERSONS WITH AN ADDITIONAL GENDER IDENTITY, GEORGIA, 2022

	PWH	I	Ever Stage 3	(AIDS)1
	N	%*	N	%*
Total	1,010	100.0	430	100.0
Gender Identity				
Transgender Woman	933	92.4	394	91.6
Transgender Man	34	3.4	14	3.3
Additional Gender Identity	43	4.3	22	5.1
Race/Ethnicity				
Black or African American/non-Hispanic	788	78.0	336	78.1
White/non-Hispanic	47	4.7	17	4.0
Hispanic/Latino, Any Race	112	11.1	51	11.9
Asian	1	0.1	1	0.2
American Indian/Alaska Native	0	0.0	0	0.0
Native Hawaiian/Pacific Islander	1	0.1	1	0.2
Multiple Races	61	6.0	24	5.6
Current Age Group (Years)				
<13	0	0.0	0	0.0
13-19	8	0.8	0	0.0
20-29	237	23.5	57	13.3
30-39	438	43.4	175	40.7
40-49	179	17.7	97	22.6
50-59	107	10.6	72	16.7
60+	41	4.1	29	6.7
HIV Transmission Category (Unadjusted)				
Sexual contact ²	927	91.8	396	92.1
Injection drug use	5	0.5	3	0.7
Sexual contact and injection drug use	43	4.3	18	4.2
Adult Other	5	0.5	3	0.7
Perinatal/other pediatric	0	0.0	0	0.0
No risk identified or reported (NIR/NRR)	30	3.0	10	2.3
HIV Transmission Category (Adjusted) ³				
Sexual contact ²	955	94.5	405	94.0
Injection drug use	8	0.7	5	1.1
Sexual contact and injection drug use	43	4.3	18	4.2
Adult Other	5	0.5	3	0.7
Perinatal/other pediatric	0	0.0	0	0.0
No risk identified or reported (NIR/NRR)	0	0.0	0	0.0

^{*} Percentages may not add up to 100% due to rounding. 1. Persons whose infection was ever classified as stage 3 (AIDS). 2. Includes sex with male and probable heterosexual transmission as noted in medical chart 3. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

HIV DIAGNOSES AND PEOPLE WITH HIV BY PUBLIC HEALTH DISTRICT

TABLE 9. HIV DIAGNOSES AND PEOPLE WITH HIV (PWH), DISTRICT 1-1 (ROME), GEORGIA, 2022

	HIV Diagr	noses	PWH	
	N	%*	N	%*
Total	71	100.0	1,374	100.0
Gender Identity				
Cisgender Male	58	81.7	997	72.6
Cisgender Female	13	18.3	367	26.7
Transgender Persons/Additional Gender Identity	0	0.0	10	0.7
Race/Ethnicity				
Black or African American/non-Hispanic	26	36.6	561	40.8
White/non-Hispanic	34	47.9	591	43.0
Hispanic/Latino, Any Race	10	14.1	125	9.1
Asian	0	0.0	9	0.7
American Indian/Alaska Native	0	0.0	0	0.0
Native Hawaiian/Pacific Islander	0	0.0	0	0.0
Multiple Races	<5		70	5.1
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	0	0.0	<5	
13-19	<5		<5	
20-29	28	39.4	157	11.4
30-39	21	29.6	266	19.4
40-49	10	14.1	264	19.2
50-59	9	12.7	366	26.6
60+	<5		315	22.9
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	34	47.9	612	44.5
Heterosexual contact ¹	11	15.5	235	17.1
Injection drug use	6	8.5	90	6.6
Male-to-male sexual contact and injection drug use	<5		68	4.9
Adult Other ²	0	0.0	18	1.3
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	17	23.9	349	25.4
HIV Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	46	64.1	773	56.3
Heterosexual contact ¹	15	21.3	364	26.5
Injection drug use	7	9.4	116	8.5
Male-to-male sexual contact and injection drug use	<5		82	6.0
Adult Other ²	0	0.0	18	1.3
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	0	0.0	18	1.3

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 10. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 1-2 (DALTON), GEORGIA, 2022

	HIV Diagr	noses	PWH	
	N	%*	N	%*
Total	27	100.0	793	100.0
Gender Identity				
Cisgender Male	16	59.3	626	78.9
Cisgender Female	8	29.6	156	19.7
Transgender Persons/Additional Gender Identity	<5		9	1.1
Race/Ethnicity				
Black or African American/non-Hispanic	7	25.9	156	19.7
White/non-Hispanic	11	40.7	426	53.7
Hispanic/Latino, Any Race	8	29.6	144	18.2
Asian	0	0.0	<5	
American Indian/Alaska Native	0	0.0	0	0.0
Native Hawaiian/Pacific Islander	0	0.0	0	0.0
Multiple Races	0	0.0	51	6.4
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	<5		<5	
13-19	<5		<5	
20-29	8	29.6	64	8.1
30-39	9	33.3	144	18.2
40-49	<5		182	23.0
50-59	<5		198	25.0
60+	<5		202	25.5
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	13	48.1	409	51.6
Heterosexual contact ¹	8	29.6	122	15.4
Injection drug use	<5		35	4.4
Male-to-male sexual contact and injection drug use	0	0.0	43	5.4
Adult Other ²	0	0.0	6	0.8
Perinatal/other pediatric ³	0	0.0	0	0.0
No risk identified or reported (NIR/NRR)	5	18.5	178	22.4
HIV Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	15	55.9	499	62.9
Heterosexual contact ¹	9	34.8	174	22.0
Injection drug use	<5		48	6.0
Male-to-male sexual contact and injection drug use	<5		51	6.4
Adult Other ²	0	0.0	6	0.8
Perinatal/other pediatric ³	0	0.0	0	0.0
No risk identified or reported (NIR/NRR)	<5		15	1.9

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion. 3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 11. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 2 (GAINESVILLE), GEORGIA, 2022

	N	%*		
		70	N	%*
Total	67	100.0	1,117	100.0
Gender Identity				
Cisgender Male	54	80.6	794	71.1
Cisgender Female	13	19.4	312	27.9
Transgender Persons/Additional Gender Identity	0	0.0	9	0.8
Race/Ethnicity				
Black or African American/non-Hispanic	17	25.4	269	24.1
White/non-Hispanic	30	44.8	525	47.0
Hispanic/Latino, Any Race	16	23.9	193	17.3
Asian	<5		26	2.3
American Indian/Alaska Native	0	0.0	<5	
Native Hawaiian/Pacific Islander	0	0.0	0	0.0
Multiple Races	<5		75	6.7
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	0	0.0	0	0.0
13-19	<5		7	0.6
20-29	19	28.4	100	9.0
30-39	14	20.9	194	17.4
40-49	16	23.9	255	22.8
50-59	12	17.9	306	27.4
60+	<5		255	22.8
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	32	47.8	480	43.0
Heterosexual contact ¹	9	13.4	193	17.3
Injection drug use	<5		48	4.3
Male-to-male sexual contact and injection drug use	<5		58	5.2
Adult Other ²	0	0.0	14	1.3
Perinatal/other pediatric ³	0	0.0	0	0.0
No risk identified or reported (NIR/NRR)	20	29.9	324	29.0
HIV Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	42	63.0	619	55.4
Heterosexual contact ¹	15	21.8	312	27.9
Injection drug use	<5		76	6.8
Male-to-male sexual contact and injection drug use	<5		69	6.1
Adult Other ²	0	0.0	14	1.3
Perinatal/other pediatric ³	0	0.0	0	0.0
No risk identified or reported (NIR/NRR)	<5		28	2.5

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 12. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 3-1 (COBB/DOUGLAS), GEORGIA, 2022

	HIV Diagn	oses	PWH	
	N	%*	N	%*
Total	211	100.0	4,801	100.0
Gender Identity				
Cisgender Male	181	85.8	3,696	77.0
Cisgender Female	25	11.8	1,014	21.1
Transgender Persons/Additional Gender Identity	5	2.4	86	1.8
Race/Ethnicity				
Black or African American/non-Hispanic	137	64.9	2,994	62.4
White/non-Hispanic	29	13.7	864	18.0
Hispanic/Latino, Any Race	37	17.5	591	12.3
Asian	0	0.0	19	0.4
American Indian/Alaska Native	0	0.0	0	0.0
Native Hawaiian/Pacific Islander	0	0.0	<5	
Multiple Races	7	3.3	293	6.1
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	0	0.0	6	0.1
13-19	9	4.3	21	0.4
20-29	91	43.1	629	13.1
30-39	59	28.0	1,268	26.4
40-49	28	13.3	1,000	20.8
50-59	13	6.2	1,100	22.9
60+	11	5.2	777	16.2
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	144	68.2	2,746	57.2
Heterosexual contact ¹	33	15.6	798	16.6
Injection drug use	<5		137	2.9
Male-to-male sexual contact and injection drug use	<5		154	3.2
Adult Other ²	0	0.0	52	1.1
Perinatal/other pediatric ³	0	0.0	6	0.1
No risk identified or reported (NIR/NRR)	30	14.2	908	18.9
HIV Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	163	77.1	3,208	66.8
Heterosexual contact ¹	41	19.4	1,117	23.3
Injection drug use	<5		194	4.0
Male-to-male sexual contact and injection drug use	<5		184	3.8
Adult Other ²	0	0.0	52	1.1
Perinatal/other pediatric ³	0	0.0	6	0.1
No risk identified or reported (NIR/NRR)	<5		40	0.8

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases<13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 13. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 3-2 (FULTON), GEORGIA, 2022

Total N %* N %* Cender Identity 526 100.0 16,975 100.0 Cisgender Male 417 79.3 14,118 83.2 Cisgender Female 93 1.7 2,551 15.0 Transgender Persons/Additional Gender Identity 16 3.0 291 1.7 Race/Ethnicity 8 394 74.9 12,346 72.7 White/non-Hispanic 54 10.3 2,371 14.0 Mispanic/Latino, Any Race 55 10.5 1,059 6.2 Asian 45 53 0.3 American Indian/Alaska Native 45 53 0.3 American Indian/Pacific Islander 0 0 0 5 Multiple Races 14 2.7 928 5.5 Age Group 4 4.6 42 0.2 42 4.6 42 0.2 20-29 193 3.8		HIV Diag	gnoses	PWH	
Gender Identity 417 79.3 14,118 83.2 Cisgender Female 93 17.7 2,551 15.0 Transgender Persons/Additional Gender Identity 16 3.0 291 1.7 Race/Ethnicity 8 0.0 291 1.7 Black or African American/non-Hispanic 394 74.9 12,346 72.7 White/non-Hispanic 54 10.3 2,371 14.0 Hispanic/Latino, Any Race 55 10.5 1,059 6.2 Asian <5 53 0.3 American Indian/Alaska Native <5 53 0.3 American Indian/Alaska Native <5 53 0.3 American Indian/Alaska Native <5 8 0.0 Age Group (24 4.6 42 0.2 4ge Group 24 4.6 42 0.2 42 da		N	%*	N	%*
Cisgender Male 417 79.3 14,118 83.2 Cisgender Female 93 17.7 2,551 15.0 Transgender Persons/Additional Gender Identity 16 3.0 291 1.7 Race/Ethnicity 394 74.9 12,346 72.7 White/non-Hispanic 54 10.3 2,371 14.0 Hispanic/Latino, Any Race 55 10.5 1,059 6.2 Asian <5	Total	526	100.0	16,975	100.0
Cisgender Female 93 17.7 2,551 15.0 Transgender Persons/Additional Gender Identity 16 3.0 291 1.7 Race/Ethnicity 8 1.0 291 1.7 Black or African American/non-Hispanic 394 74.9 12,346 72.7 White/non-Hispanic 54 10.3 2,371 14.0 Hispanic/Latino, Any Race 55 10.5 1,059 6.2 Asian <5 53 0.3 American Indian/Alaska Native <5 53 0.0 Native Hawaiian/Pacific Islander 0 0.0 <5 Multiple Races 14 2.7 928 5.5 Age Group 4 2.7 928 5.5 Age Group 4 2.7 928 5.5 Age Group 2 4 4.6 42 0.2 13-19 2 4 6.6 42 0.2 0-2-9 192 <td>Gender Identity</td> <td></td> <td></td> <td></td> <td></td>	Gender Identity				
Transgender Persons/Additional Gender Identity 16 3.0 291 1.7 Race/Ethnicity Black or African American/non-Hispanic 394 74.9 12,346 72.7 White/non-Hispanic 54 10.3 2,371 14.0 Hispanic/Latino, Any Race 55 10.5 1,059 6.2 Asian <5 53 0.3 American Indian/Alaska Native 0 0.0 <5 Multiple Races 14 2.7 928 5.5 Age Group (at diagnosis for diagnosed, current for PWH) 9 0.1 13-19 24 4.6 42 0.2 0.2 20-29 192 36.5 1,565 9.2 30-39 178 33.8 4,576 27.0 60+ 29 49 9.3 4,029 23.7 60+ 49 9.3 4,029 23.7 HIV Transmission Category (Unadjusted) 32 61.2 10	Cisgender Male	417	79.3	14,118	83.2
Race/Ethnicity Black or African American/non-Hispanic 394 74.9 12,346 72.7 14.0 White/non-Hispanic 54 10.3 2,371 14.0 Hispanic/Latino, Any Race 55 10.5 1,059 6.2 6.2 6.3	Cisgender Female	93	17.7	2,551	15.0
Black or African American/non-Hispanic 394 74.9 12,346 72.7 White/non-Hispanic 54 10.3 2,371 14.0 Hispanic/Latino, Any Race 55 10.5 1,059 6.2 Asian <5 53 0.3 American Indian/Alaska Native <5 8 0.0 Native Hawaiian/Pacific Islander 0 0.0 <5 Multiple Races 14 2.7 928 5.5 Secondary S	Transgender Persons/Additional Gender Identity	16	3.0	291	1.7
White/non-Hispanic 54 10.3 2,371 14.0 Hispanic/Latino, Any Race 55 10.5 1,059 6.2 Asian <5	Race/Ethnicity				
Hispanic/Latino, Any Race	Black or African American/non-Hispanic	394	74.9	12,346	72.7
Asian <5	White/non-Hispanic	54	10.3	2,371	14.0
American Indian/Alaska Native <5 8 0.0 Native Hawaiian/Pacific Islander 0 0.0 <5 Multiple Races 14 2.7 928 5.5 Age Group (at diagnosis for diagnosed, current for PWH) C C 9 0.1 413-19 24 4.6 42 0.2 20-29 192 36.5 1,565 9.2 30-39 178 33.8 4,576 27.0 40-49 58 11.0 3,468 20.4 50-59 49 9.3 4,029 23.7 60+ 23 4.4 3,280 19.3 HIV Transmission Category (Unadjusted) 322 61.2 10,797 63.6 Heterosexual contact ¹ 115 21.9 1,977 61.6 Injection drug use 5 650 3.8 Adult Other ² 0 0 0 9 0.6 Perinatal/other pediatric³	Hispanic/Latino, Any Race	55	10.5	1,059	6.2
Native Hawaiian/Pacific Islander 0 0.0 <5	Asian	<5		53	0.3
Multiple Races 14 2.7 928 5.5 Age Group (at diagnosis for diagnosed, current for PWH)	American Indian/Alaska Native	<5		8	0.0
Age Group (at diagnosic for diagnosed, current for PWH) 13-19	Native Hawaiian/Pacific Islander	0	0.0	<5	
Cat diagnosis for diagnosed, current for PWH) Cat Cat	Multiple Races	14	2.7	928	5.5
413 <5	Age Group				
13-19	(at diagnosis for diagnosed, current for PWH)				
192 36.5 1,565 9.2 30-39 178 33.8 4,576 27.0 40-49 58 11.0 3,468 20.4 50-59 49 9.3 4,029 23.7 60+ 23 4.4 3,280 19.3 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 322 61.2 10,797 63.6 Heterosexual contact 115 21.9 1,977 11.6 Injection drug use 9 1.7 583 3.4 Male-to-male sexual contact and injection drug use 5 650 3.8 Adult Other 2 0 0.0 99 0.6 Perinatal/other pediatric 368 70.0 12,297 72.4 Heterosexual contact 133 25.3 2,854 16.8 Injection drug use 12 2.2 753 4.4 Male-to-male sexual contact and injection drug use 5 1.0 758 4.5 Adult Other 2 0 0.0 99 0.6 Perinatal/other pediatric 3 4.5 9 0.1 Male-to-male sexual contact 133 25.3 2,854 16.8 Injection drug use 12 2.2 753 4.4 Male-to-male sexual contact and injection drug use 5 1.0 758 4.5 Adult Other 2 0 0.0 99 0.6 Perinatal/other pediatric 3 5 5 9 0.1 Perinatal/other pediatric 5 5 5 5 5 5 Reference 9 0.1 Reference 9 0.	<13	<5		9	0.1
30-39 178 33.8 4,576 27.0 40-49 58 11.0 3,468 20.4 50-59 49 9.3 4,029 23.7 60+ 23 4.4 3,280 19.3 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 322 61.2 10,797 63.6 Heterosexual contact ¹ 115 21.9 1,977 11.6 Injection drug use 9 1.7 583 3.4 Male-to-male sexual contact and injection drug use <5	13-19	24	4.6	42	0.2
40-49 58 11.0 3,468 20.4 50-59 49 9.3 4,029 23.7 60+ 23 4.4 3,280 19.3 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 322 61.2 10,797 63.6 Heterosexual contact ¹ 115 21.9 1,977 11.6 Injection drug use 9 1.7 583 3.4 Male-to-male sexual contact and injection drug use <5	20-29	192	36.5	1,565	9.2
50-59 49 9.3 4,029 23.7 60+ 23 4.4 3,280 19.3 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 322 61.2 10,797 63.6 Heterosexual contact¹ 115 21.9 1,977 11.6 Injection drug use 9 1.7 583 3.4 Male-to-male sexual contact and injection drug use <5	30-39	178	33.8	4,576	27.0
HIV Transmission Category (Unadjusted) Male-to-male sexual contact 322 61.2 10,797 63.6 Heterosexual contact 115 21.9 1,977 11.6 Injection drug use 9 1.7 583 3.4 Male-to-male sexual contact and injection drug use 5 650 3.8 Adult Other 0 0.0 99 0.6 Perinatal/other pediatric 3 5 9 0.1 No risk identified or reported (NIR/NRR) 74 14.1 2,860 16.8 HIV Transmission Category (Adjusted) 4 Heterosexual contact 368 70.0 12,297 72.4 Heterosexual contact 133 25.3 2,854 16.8 Injection drug use 12 2.2 753 4.4 Male-to-male sexual contact and injection drug use 5 1.0 758 4.5 Adult Other 0 0.0 99 0.6 Perinatal/other pediatric 5 9 0.1 Perinatal/other pediatric 5 9 0.1 Perinatal/other pediatric 5 9 0.1	40-49	58	11.0	3,468	20.4
HIV Transmission Category (Unadjusted) Male-to-male sexual contact 322 61.2 10,797 63.6 Heterosexual contact¹ 115 21.9 1,977 11.6 Injection drug use 9 1.7 583 3.4 Male-to-male sexual contact and injection drug use <5	50-59	49	9.3	4,029	23.7
Male-to-male sexual contact 322 61.2 10,797 63.6 Heterosexual contact¹ 115 21.9 1,977 11.6 Injection drug use 9 1.7 583 3.4 Male-to-male sexual contact and injection drug use <5	60+	23	4.4	3,280	19.3
Heterosexual contact¹ 115 21.9 1,977 11.6	HIV Transmission Category (Unadjusted)				
Injection drug use 9 1.7 583 3.4 Male-to-male sexual contact and injection drug use <5 650 3.8 Adult Other² 0 0.0 99 0.6 Perinatal/other pediatric³ <5 9 0.1 No risk identified or reported (NIR/NRR) 74 14.1 2,860 16.8 HIV Transmission Category (Adjusted)⁴ Male-to-male sexual contact 368 70.0 12,297 72.4 Heterosexual contact¹ 133 25.3 2,854 16.8 Injection drug use 12 2.2 753 4.4 Male-to-male sexual contact and injection drug use 5 1.0 758 4.5 Adult Other² 0 0.0 99 0.6 Perinatal/other pediatric³ <5 9 0.1	Male-to-male sexual contact	322	61.2	10,797	63.6
Male-to-male sexual contact and injection drug use <5	Heterosexual contact ¹	115	21.9	1,977	11.6
Adult Other² 0 0.0 99 0.6 Perinatal/other pediatric³ <5	Injection drug use	9	1.7	583	3.4
Perinatal/other pediatric³ <5 9 0.1 No risk identified or reported (NIR/NRR) 74 14.1 2,860 16.8 HIV Transmission Category (Adjusted)⁴ 8 70.0 12,297 72.4 Heterosexual contact¹ 133 25.3 2,854 16.8 Injection drug use 12 2.2 753 4.4 Male-to-male sexual contact and injection drug use 5 1.0 758 4.5 Adult Other² 0 0.0 99 0.6 Perinatal/other pediatric³ <5 9 0.1	Male-to-male sexual contact and injection drug use	<5		650	3.8
No risk identified or reported (NIR/NRR) 74 14.1 2,860 16.8 HIV Transmission Category (Adjusted) ⁴ Male-to-male sexual contact 368 70.0 12,297 72.4 Heterosexual contact ¹ 133 25.3 2,854 16.8 Injection drug use 12 2.2 753 4.4 Male-to-male sexual contact and injection drug use 5 1.0 758 4.5 Adult Other ² 0 0.0 99 0.6 Perinatal/other pediatric ³ <5	Adult Other ²	0	0.0	99	0.6
HIV Transmission Category (Adjusted) ⁴ Male-to-male sexual contact 368 70.0 12,297 72.4 Heterosexual contact ¹ 133 25.3 2,854 16.8 Injection drug use 12 2.2 753 4.4 Male-to-male sexual contact and injection drug use 5 1.0 758 4.5 Adult Other ² 0 0.0 99 0.6 Perinatal/other pediatric ³ <5	Perinatal/other pediatric ³	<5		9	0.1
Male-to-male sexual contact 368 70.0 12,297 72.4 Heterosexual contact¹ 133 25.3 2,854 16.8 Injection drug use 12 2.2 753 4.4 Male-to-male sexual contact and injection drug use 5 1.0 758 4.5 Adult Other² 0 0.0 99 0.6 Perinatal/other pediatric³ <5	No risk identified or reported (NIR/NRR)	74	14.1	2,860	16.8
Heterosexual contact¹ 133 25.3 2,854 16.8 Injection drug use 12 2.2 753 4.4 Male-to-male sexual contact and injection drug use 5 1.0 758 4.5 Adult Other² 0 0.0 99 0.6 Perinatal/other pediatric³ <5	HIV Transmission Category (Adjusted) ⁴				
Injection drug use 12 2.2 753 4.4 Male-to-male sexual contact and injection drug use 5 1.0 758 4.5 Adult Other ² 0 0.0 99 0.6 Perinatal/other pediatric ³ <5	Male-to-male sexual contact	368	70.0	12,297	72.4
Male-to-male sexual contact and injection drug use 5 1.0 758 4.5 Adult Other 2 0 0.0 99 0.6 Perinatal/other pediatric 3 <5 9 0.1	Heterosexual contact ¹	133	25.3	2,854	16.8
Adult Other ² 0 0.0 99 0.6 Perinatal/other pediatric ³ $<$ 5 9 0.1	Injection drug use	12	2.2	753	4.4
Perinatal/other pediatric ³ <5 9 0.1	Male-to-male sexual contact and injection drug use	5	1.0	758	4.5
	Adult Other ²	0	0.0	99	0.6
No risk identified or reported (NIR/NRR) 6 1.1 204 1.2	Perinatal/other pediatric ³	<5		9	0.1
201 212	No risk identified or reported (NIR/NRR)	6	1.1	204	1.2

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 14. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 3-3 (CLAYTON), GEORGIA, 2022

Total N N* N N* Cender Identity Cender Identity 78.3 2,462 73.3 Cisgender Female 27 18.9 822 24.5 Transgender Persons/Additional Gender Identity 8 27 18.9 822 24.5 Transgender Persons/Additional Gender Identity 8 27 18.9 822 24.5 Transgender Persons/Additional Gender Identity 8 8 27 18.9 822 24.5 Transgender Persons/Additional Gender Identity 8 8 2 12.2 3.6 Mercer African American/Indexide/Indexi		HIV Diag	gnoses	PWH	
Gender Identity 112 78.3 2,462 73.3 Cisgender Female 27 18.9 822 24.5 Transgender Persons/Additional Gender Identity 45 73 2.2 Race/Ethnicity 8 73 2.2 White/non-Hispanic 113 79.0 2,773 82.6 White/non-Hispanic 21 14.7 225 6.67 Asian 45 12 0.8 American Indian/Alaska Native 0 0 45 Multiple Races 45 172 5.1 Age Group (at diagnosis for diagnosed, current for PWH) 4 0 0 4 5.1 13-19 7 4.9 16 0.5 1.2 1.2 13-29 4 3 4.0 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2		N	%*	N	%*
Cisgender Male 112 78.3 2,462 73.3 Cisgender Female 27 18.9 822 24.5 Transgender Persons/Additional Gender Identity 5 73 2.2 Race/Ethnicty 12 2.773 82.6 White/non-Hispanic 113 79.0 2,773 82.6 Hilspanic/Latino, Any Race 21 14.7 225 6.7 Asian 0 0 0.8 Asian Again (Malay Native 0 0 0.8 American Indian/Alaska Native 0 0 0.8 Multiple Races -5 172 5.1 Age Group (adjusted Standard Contact (Agency Contract for PWH) 17 4.9 1.0 0.2 413-19 7 4.9 1.0 0.2 1.2 1.0 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	Total	143	100.0	3,357	100.0
Cisgender Female 27 18.9 822 24.5 Transgender Persons/Additional Gender Identity 45 73 2.2 Race/Ethnicity 45 73 2.2 Black or African American/non-Hispanic 113 79.0 2,773 8.26 White/non-Hispanic 45 122 3.6 Hispanic/Latino, Any Race 21 14.7 225 6.7 Asian 5 27 0.8 American Indian/Alaska Native 0 0.0 <5 Native Hawaiian/Pacific Islander 0 0.0 <5 Multiple Races 45 10.2 5.1 Age Group 2 10.2 5.1 45 13 0 0 0 0 21 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0<	Gender Identity				
Transgender Persons/Additional Gender Identity <5 73 2.2 Race/Ethnicity Black or African American/non-Hispanic 113 79.0 2,773 82.6 Hispanic/Latino, Any Race 21 14.7 225 6.7 Asian <5 27 0.8 American Indian/Alaska Native 0 0.0 <5 Native Hawaiian/Pacific Islander 0 0 0 5 Native Hawaiian/Pacific Islander 0 0 0 5 172 Native Hawaiian/Pacific Islander 0 0 0 6 0 2 Age Group (that Bawaiian Pacific Islander 0 0 0 0 0 0 0 0 0 0	Cisgender Male	112	78.3	2,462	73.3
Black or African American/non-Hispanic 113 79.0 2,773 82.6 2.6 White/non-Hispanic 5 122 3.6 1.6	Cisgender Female	27	18.9	822	24.5
Black or African American/non-Hispanic 113 79.0 2,773 82.6 White/non-Hispanic <5	Transgender Persons/Additional Gender Identity	<5		73	2.2
White/non-Hispanic <5 122 3.6 Hispanic/Latino, Any Race 21 14.7 225 6.7 Asian <5 27 0.8 American Indian/Alaska Native 0 0.0 <5 Native Hawaiian/Pacific Islander 0 0.0 <5 Multiple Races <5 172 5.1 Age Group (at diagnosis for diagnosed, current for PWH) 172 5.1 43 0 0 0 6 0.2 13-19 7 4.9 16 0.5 20-29 59 41.3 420 12.5 30-39 40-49 12. 45 31.5 1,004 29.9 40-49 12. 45 31.5 1,004 29.9 40-49 40-49 40-49 40-49 40-49 40-49 40-49 40-49 40-49 40-49 40-49 40-49 40-49 40-49 40-49 40-49 40-49 40-49	Race/Ethnicity				
Hispanic/Latino, Any Race	Black or African American/non-Hispanic	113	79.0	2,773	82.6
Asian <5 27 0.8 American Indian/Alaska Native 0 0.0 <5 Native Hawaiian/Pacific Islander 0 0.0 <5 Multiple Races <5 172 5.1 Age Group (at diagnosis for diagnosed, current for PWH) 172 5.1 43-19 0 0 6 0.2 1.5 1.00 6 0.2 30-29 41.3 420 1.5 1.00 29. 1.2 30-39 41.3 420 12.5 30-39 45 31.5 1,004 29. 40-49 50-49 49. 49. 49. 49. 49. 40. 49. 60. 40. 49. 69. 20. 40. 49. 49. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40. 40	White/non-Hispanic	<5		122	3.6
American Indian/Alaska Native 0 0.0 <5 —— Native Hawaiian/Pacific Islander 0 0.0 <5	Hispanic/Latino, Any Race	21	14.7	225	6.7
Native Hawaiian/Pacific Islander 0 0.0 <5	Asian	<5		27	0.8
Multiple Races 45	American Indian/Alaska Native	0	0.0	<5	
Age Group (at diagnosis for diagnosed, current for PWH)	Native Hawaiian/Pacific Islander	0	0.0	<5	
ctal diagnosis for diagnosed, current for PWH) C 13 0 0.0 6 0.2 13-19 7 4.9 16 0.5 20-29 59 41.3 420 12.5 30-39 45 31.5 1,004 29.9 40-49 22 15.4 715 21.3 50-59 7 4.9 698 20.8 60+ 5 498 14.8 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 91 63.6 1,857 55.3 Heterosexual contact ¹ 34 23.8 600 17.9 Injection drug use 0 0.0 93 2.8 Male-to-male sexual contact and injection drug use 0 0.0 35 1.0 Horizandi/other pediatric ³ 0 0.0 5 2.0 HIV Transmission Category (Adjusted) ⁴ 18 12.6 671 2.0 Hiv Transmission Category (Adjusted) ⁴ 41 28.8 893 26.6 Injection drug use <5	Multiple Races	<5		172	5.1
<13	Age Group				
13-19 7 4.9 16 0.5 20-29 59 41.3 420 12.5 30-39 45 31.5 1,004 29.9 40-49 22 15.4 715 21.3 50-59 7 4.9 698 20.8 60+ <5	(at diagnosis for diagnosed, current for PWH)				
20-29 59 41.3 420 12.5 30-39 45 31.5 1,004 29.9 40-49 22 15.4 715 21.3 50-59 7 4.9 698 20.8 60+ <5	<13	0	0.0	6	0.2
30-39 45 31.5 1,004 29.3 40-49 22 15.4 715 21.3 50-59 7 4.9 698 20.8 60+ <5	13-19	7	4.9	16	0.5
40-49 22 15.4 715 21.3 50-59 7 4.9 698 20.8 60+ <5	20-29	59	41.3	420	12.5
50-59 7 4.9 698 20.8 60+ <5	30-39	45	31.5	1,004	29.9
60+ <5 498 14.8 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 91 63.6 1,857 55.3 Heterosexual contact¹ 34 23.8 600 17.9 Injection drug use 0 0.0 93 2.8 Male-to-male sexual contact and injection drug use 0 0.0 96 2.9 Adult Other² 0 0.0 35 1.0 Perinatal/other pediatric³ 0 0.0 5 0.1 No risk identified or reported (NIR/NRR) 18 12.6 671 20.0 HIV Transmission Category (Adjusted)⁴ 8 12.6 671 20.0 Heterosexual contact¹ 99 69.1 2,139 63.7 Heterosexual contact¹ 41 28.8 893 26.6 Injection drug use <5	40-49	22	15.4	715	21.3
HIV Transmission Category (Unadjusted) Male-to-male sexual contact 91 63.6 1,857 55.3 Heterosexual contact¹ 34 23.8 600 17.9 Injection drug use 0 0.0 93 2.8 Male-to-male sexual contact and injection drug use 0 0.0 96 2.9 Adult Other² 0 0.0 35 1.0 Perinatal/other pediatric³ 0 0.0 5 0.1 No risk identified or reported (NIR/NRR) 18 12.6 671 20.0 HIV Transmission Category (Adjusted)⁴ 8 12.6 671 20.0 Male-to-male sexual contact 99 69.1 2,139 63.7 Heterosexual contact¹ 41 28.8 893 26.6 Injection drug use <5	50-59	7	4.9	698	20.8
Male-to-male sexual contact 91 63.6 1,857 55.3 Heterosexual contact¹ 34 23.8 600 17.9 Injection drug use 0 0.0 93 2.8 Male-to-male sexual contact and injection drug use 0 0.0 96 2.9 Adult Other² 0 0.0 35 1.0 Perinatal/other pediatric³ 0 0.0 5 0.1 No risk identified or reported (NIR/NRR) 18 12.6 671 20.0 HIV Transmission Category (Adjusted)⁴ 8 12.6 671 20.0 Male-to-male sexual contact 99 69.1 2,139 63.7 Heterosexual contact¹ 41 28.8 893 26.6 Injection drug use <5	60+	<5		498	14.8
Heterosexual contact¹ 34 23.8 600 17.9 Injection drug use 0 0.0 93 2.8 Male-to-male sexual contact and injection drug use 0 0.0 96 2.9 Adult Other² 0 0.0 35 1.0 Perinatal/other pediatric³ 0 0.0 5 0.1 No risk identified or reported (NIR/NRR) 18 12.6 671 20.0 HIV Transmission Category (Adjusted)⁴ 8 12.6 671 20.0 Male-to-male sexual contact 99 69.1 2,139 63.7 Heterosexual contact¹ 41 28.8 893 26.6 Injection drug use <5	HIV Transmission Category (Unadjusted)				
Injection drug use 0 0.0 93 2.8 Male-to-male sexual contact and injection drug use 0 0.0 96 2.9 Adult Other² 0 0.0 35 1.0 Perinatal/other pediatric³ 0 0.0 5 0.1 No risk identified or reported (NIR/NRR) 18 12.6 671 20.0 HIV Transmission Category (Adjusted)⁴ 2,139 63.7 Heterosexual contact¹ 41 28.8 893 26.6 Injection drug use <5 136 4.1 Male-to-male sexual contact and injection drug use <5 117 3.5 Adult Other² 0 0.0 35 1.0 Perinatal/other pediatric³ 0 0.0 5 0.1	Male-to-male sexual contact	91	63.6	1,857	55.3
Male-to-male sexual contact and injection drug use 0 0.0 96 2.9 Adult Other² 0 0.0 35 1.0 Perinatal/other pediatric³ 0 0.0 5 0.1 No risk identified or reported (NIR/NRR) 18 12.6 671 20.0 HIV Transmission Category (Adjusted)⁴ 8 40 2,139 63.7 Heterosexual contact¹ 41 28.8 893 26.6 Injection drug use <5	Heterosexual contact ¹	34	23.8	600	17.9
Adult Other² 0 0.0 35 1.0 Perinatal/other pediatric³ 0 0.0 5 0.1 No risk identified or reported (NIR/NRR) 18 12.6 671 20.0 HIV Transmission Category (Adjusted)⁴ Male-to-male sexual contact 99 69.1 2,139 63.7 Heterosexual contact¹ 41 28.8 893 26.6 Injection drug use <5	Injection drug use	0	0.0	93	2.8
Perinatal/other pediatric³ 0 0.0 5 0.1 No risk identified or reported (NIR/NRR) 18 12.6 671 20.0 HIV Transmission Category (Adjusted)⁴ V V V V C C C 2,139 63.7 Ad.7 Ad.8 893 26.6 Ad.9	Male-to-male sexual contact and injection drug use	0	0.0	96	2.9
No risk identified or reported (NIR/NRR) 18 12.6 671 20.0 HIV Transmission Category (Adjusted) ⁴ Male-to-male sexual contact 99 69.1 2,139 63.7 Heterosexual contact ¹ 41 28.8 893 26.6 Injection drug use <5	Adult Other ²	0	0.0	35	1.0
HIV Transmission Category (Adjusted) ⁴ Male-to-male sexual contact 99 69.1 2,139 63.7 Heterosexual contact ¹ 41 28.8 893 26.6 Injection drug use <5	Perinatal/other pediatric ³	0	0.0	5	0.1
Male-to-male sexual contact 99 69.1 2,139 63.7 Heterosexual contact¹ 41 28.8 893 26.6 Injection drug use <5	No risk identified or reported (NIR/NRR)	18	12.6	671	20.0
Heterosexual contact¹ 41 28.8 893 26.6 Injection drug use <5	HIV Transmission Category (Adjusted) ⁴				
Injection drug use <5 136 4.1 Male-to-male sexual contact and injection drug use <5 117 3.5 Adult Other ² 0 0.0 35 1.0 Perinatal/other pediatric ³ 0 0.0 5	Male-to-male sexual contact	99	69.1	2,139	63.7
Male-to-male sexual contact and injection drug use <5 117 3.5 Adult Other ² 0 0.0 35 1.0 Perinatal/other pediatric ³ 0 0.0 5 0.1	Heterosexual contact ¹	41	28.8	893	26.6
Adult Other² 0 0.0 35 1.0 Perinatal/other pediatric³ 0 0.0 5 0.1	Injection drug use	<5		136	4.1
Adult Other² 0 0.0 35 1.0 Perinatal/other pediatric³ 0 0.0 5 0.1	Male-to-male sexual contact and injection drug use	<5		117	3.5
	Adult Other ²	0	0.0	35	1.0
	Perinatal/other pediatric ³	0	0.0	5	0.1
	No risk identified or reported (NIR/NRR)	<5		32	

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 15. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 3-4 (EAST METRO), GEORGIA, 2022

	HIV Diag	noses	PWH	
	N	%*	N	%*
Total	265	100.0	5,102	100.0
Gender Identity				
Cisgender Male	216	81.5	3,682	72.2
Cisgender Female	46	17.4	1,351	26.5
Transgender Persons/Additional Gender Identity	<5		65	1.3
Race/Ethnicity				
Black or African American/non-Hispanic	121	45.7	3,029	59.4
White/non-Hispanic	24	9.1	696	13.6
Hispanic/Latino, Any Race	101	38.1	937	18.4
Asian	7	2.6	85	1.7
American Indian/Alaska Native	0	0.0	<5	
Native Hawaiian/Pacific Islander	0	0.0	<5	
Multiple Races	7	2.6	273	5.4
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	0	0.0	11	0.2
13-19	21	7.9	33	0.6
20-29	85	32.1	623	12.2
30-39	76	28.7	1,238	24.3
40-49	44	16.6	1,093	21.4
50-59	28	10.6	1,269	24.9
60+	11	4.2	835	16.4
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	161	60.8	2,604	51.0
Heterosexual contact ¹	39	14.7	916	18.0
Injection drug use	7	2.6	158	3.1
Male-to-male sexual contact and injection drug use	<5		108	2.1
Adult Other ²	0	0.0	43	0.8
Perinatal/other pediatric ³	0	0.0	11	0.2
No risk identified or reported (NIR/NRR)	54	20.4	1,262	24.7
HIV Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	193	73.0	3,152	61.8
Heterosexual contact ¹	52	19.6	1,432	28.1
Injection drug use	9	3.5	239	4.7
Male-to-male sexual contact and injection drug use	5	2.0	148	2.9
Adult Other ²	0	0.0	43	0.8
Perinatal/other pediatric ³	0	0.0	11	0.2
No risk identified or reported (NIR/NRR)	5	1.9	77	1.5

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 16. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 3-5 (DEKALB), GEORGIA, 2022

Total 372 100.0 10,219 100.0 Gender Identity Cisgender Male 318 85.5 8,161 79.9 Cisgender Female 47 12.6 1,857 18.2 Transgender Persons/Additional Gender Identity 8 1.9 191 1.9 Race/Ethnicity 8 7 1.9 191 1.9 Black or African American/non-Hispanic 285 76.6 7,310 71.5 White/non-Hispanic 35 9.4 1,416 13.9 Asian 6 1.6 73 0.7 American Indian/Alaska Native 0 0.0 <5		HIV Dia	gnoses	P۱	VH
Gender Identity 318 85.5 8,161 79.9 Cisgender Female 47 12.6 1,857 18.2 Transgender Persons/Additional Gender Identity 7 1.9 191 1.9 Race/Ethnicity 8 7 1.9 191 1.9 Black or African American/non-Hispanic 285 76.6 7,310 71.5 White/non-Hispanic 35 9.4 1,416 13.9 Hispanic/Latino, Any Race 37 9.9 808 7.9 Asian 6 1.6 73 0.7 American Indian/Alaska Native 0 0.0 0.5 0.0 Multiple Races 7 1.9 494 4.8 Age Group 4 48 3.0 9 0.4 413 3.19 11 3.0 39 0.4 40-2.9 142 38.2 991 9.7 30-39 109 29.3 2,568 25.5 40-49 48 <td< th=""><th></th><th>N</th><th>%*</th><th>N</th><th>%*</th></td<>		N	%*	N	%*
Cisgender Male 318 85.5 8,161 79.9 Cisgender Female 47 12.6 1,857 18.2 Transgender Persons/Additional Gender Identity 7 1.9 191 1.9 Race/Ethnicity 8 5 76.6 7,310 71.5 White/non-Hispanic 35 9.4 1,416 13.9 Hispanic/Latino, Any Race 37 9.9 808 7.9 Asian 6 1.6 73 0.7 American Indian/Alaska Native 0 0.0 <5	Total	372	100.0	10,219	100.0
Cisgender Female 47 12.6 1,857 18.2 Transgender Persons/Additional Gender Identity 7 1.9 191 1.9 Race/Ethnicity Black or African American/non-Hispanic 285 76.6 7,310 71.5 White/non-Hispanic 35 9.4 1,416 13.9 Hispanic/Latino, Any Race 37 9.9 808 7.9 Asian 6 1.6 73 0.7 American Indian/Alaska Native 0 0.0 5 0.0 Nultiple Races 7 1.9 494 4.8 Age Group 4 4.8 4.8 4.8 4.6 4.8 4.8 4.8 4.9 4.8 4.8 4.8 4.9 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.9 4.8 4.8 4.9 4.8 4.2 9.9 4.4 3.8	Gender Identity				
Transgender Persons/Additional Gender Identity 7 1.9 191 1.9 Race/Etthnicity Black or African American/non-Hispanic 285 76.6 7,310 71.5 White/non-Hispanic 35 9.4 1,416 13.9 Hispanic/Latino, Any Race 37 9.9 808 7.9 Asian 6 1.6 73 0.7 American Indian/Alaska Native 0 0.0 <5 Native Hawaiian/Pacific Islander 0 0.0 <5 Multiple Races 7 1.9 494 4.8 Age Group (at diagnosed, current for PWH) <5 11 0.1 4.13 < <5 11 0.1 13-19 11 3.0 39 0.4 20-29 142 38.2 991 9.7 30-39 109 29.3 2,608 25.5 40-49 48 12.9 2,080 20.4	Cisgender Male	318	85.5	8,161	79.9
Race/Ethnicity Black or African American/non-Hispanic 285 76.6 7,310 71.5 White/non-Hispanic 35 9.4 1,416 13.9 Hispanic/Latino, Any Race 37 9.9 808 7.9 Asian 6 1.6 73 0.7 American Indian/Alaska Native 0 0.0 <5 American Indian/Alaska Native 0 0.0 5 0.0 Multiple Races 7 1.9 494 4.8 Age Group (lat diagnosis for diagnosed, current for PWH) 11 3.0 39 0.4 20-29 142 38.2 991 9.7 30-39 109 29.3 2,608 25.5 40-49 48 12.9 2,080 20.4 50-59 39 10.5 2,516 24.6 60+ 22 5.9 1,973 19.3 HIV Transmission Category (Unadjusted) 1.40 1.30 Male-to-male sexual contact 250 67.2 6,232 61.0 Heterosexual contact 250 67.2 6,232 61.0 Male-to-male sexual contact and injection drug use 5 1.3 2.36 2.3 Male-to-male sexual contact and injection drug use 5 1.3 2.36 2.3 Male-to-male sexual contact and injection drug use 5 1.3 2.36 2.3 Male-to-male sexual contact 250 67.2 299 2.9 Adult Other 2 0 0.0 77 0.8 Perinatal/other pediatric 74 19.9 2,087 20.4 Male-to-male sexual contact 74 19.9 2,087 3.6 Male-to-male sexual contact		47	12.6	1,857	18.2
Black or African American/non-Hispanic 285 76.6 7,310 71.5	Transgender Persons/Additional Gender Identity	7	1.9	191	1.9
White/non-Hispanic 35 9.4 1,416 13.9 Hispanic/Latino, Any Race 37 9.9 808 7.9 Asian 6 1.6 73 0.7 American Indian/Alaska Native 0 0.0 5 0.0 Multiple Races 7 1.9 494 4.8 Age Group (at diagnosis for diagnosed, current for PWH) 1.1 9.0 9.	Race/Ethnicity				
Hispanic/Latino, Any Race	Black or African American/non-Hispanic	285	76.6	7,310	71.5
Asian 6 1.6 73 0.7 American Indian/Alaska Native 0 0.0 <5 Native Hawaiian/Pacific Islander 0 0.0 5 0.0 Multiple Races 7 1.9 494 4.8 Age Group (at diagnosis for diagnosed, current for PWH) *** *** 11 0.1 4.13 <5 11 0.1 13-19 11 3.0 39 0.4 20-29 142 38.2 991 9.7 30-39 109 29.3 2,608 25.5 40-49 48 12.9 2,080 20.4 60+ 2 5.9 1,973 19.3 HIV Transmission Category (Unadjusted) 2 6.232 61.0 Male-to-male sexual contact ¹ 5 1.3 236 2.3 Male-to-male sexual contact and injection drug use 45 10 0.1 No risk identified or reported (NIR/NRR) 7 15.3	White/non-Hispanic	35	9.4	1,416	13.9
American Indian/Alaska Native 0 0.0 <5 Native Hawaiian/Pacific Islander 0 0.0 5 0.0 Multiple Races 7 1.9 494 4.8 Age Group (at diagnosis for diagnosed, current for PWH) ************************************	Hispanic/Latino, Any Race	37	9.9	808	7.9
Native Hawaiian/Pacific Islander 0 0.0 5 0.0 Multiple Races 7 1.9 494 4.8 Age Group (lat diagnosis for diagnosed, current for PWH) 8 8 8 8 11 0.1 <13-19 11 3.0 39 0.4 20-29 142 38.2 991 9.7 30-39 109 29.3 2,608 25.5 40-49 48 12.9 2,080 20.4 50-59 39 10.5 2,516 24.6 60+ 2 5.9 1,973 19.3 HIV Transmission Category (Unadjusted) 2 67.2 6,232 61.0 Heterosexual contact ¹ 58 15.6 1,409 13.8 Injection drug use 5 1.3 236 2.3 Male-to-male sexual contact and injection drug use 5 10 0.1 No risk identified or reported (NIR/NR) 57 15.3 1,956 19.1 HIV Transmission Category (Adjusted) ⁴ 285 76.6 7,188 70.3	Asian	6	1.6	73	0.7
Multiple Races 7 1.9 494 4.8 Age Group (at diagnosis for diagnosed, current for PWH) <13	American Indian/Alaska Native	0	0.0	<5	
Age Group (at diagnosis for diagnosed, current for PWH) 13 15 17 18 19 11 18 19 19 19 19	Native Hawaiian/Pacific Islander	0	0.0	5	0.0
Claim Clai	Multiple Races	7	1.9	494	4.8
413 <5	Age Group				
13-19 11 3.0 39 0.4 20-29 142 38.2 991 9.7 30-39 109 29.3 2,608 25.5 40-49 48 12.9 2,080 20.4 50-59 39 10.5 2,516 24.6 60+ 22 5.9 1,973 19.3 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 250 67.2 6,232 61.0 Heterosexual contact ¹ 58 15.6 1,409 13.8 Injection drug use 5 1.3 236 2.3 Male-to-male sexual contact and injection drug use <5	(at diagnosis for diagnosed, current for PWH)				
20-29 142 38.2 991 9.7 30-39 109 29.3 2,608 25.5 40-49 48 12.9 2,080 20.4 50-59 39 10.5 2,516 24.6 60+ 22 5.9 1,973 19.3 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 250 67.2 6,232 61.0 Heterosexual contact ¹ 58 15.6 1,409 13.8 Injection drug use 5 1.3 236 2.3 Male-to-male sexual contact and injection drug use <5	<13	<5		11	0.1
30-39 109 29.3 2,608 25.5 40-49 48 12.9 2,080 20.4 50-59 39 10.5 2,516 24.6 60+ 22 5.9 1,973 19.3 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 250 67.2 6,232 61.0 Heterosexual contact ¹ 58 15.6 1,409 13.8 Injection drug use 5 1.3 236 2.3 Male-to-male sexual contact and injection drug use <5	13-19	11	3.0	39	0.4
40-49 48 12.9 2,080 20.4 50-59 39 10.5 2,516 24.6 60+ 22 5.9 1,973 19.3 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 250 67.2 6,232 61.0 Heterosexual contact ¹ 58 15.6 1,409 13.8 Injection drug use 5 1.3 236 2.3 Male-to-male sexual contact and injection drug use <5	20-29	142	38.2	991	9.7
50-59 39 10.5 2,516 24.6 60+ 22 5.9 1,973 19.3 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 250 67.2 6,232 61.0 Heterosexual contact¹ 58 15.6 1,409 13.8 Injection drug use 5 1.3 236 2.3 Male-to-male sexual contact and injection drug use <5	30-39	109	29.3	2,608	25.5
60+ 22 5.9 1,973 19.3 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 250 67.2 6,232 61.0 Heterosexual contact¹ 58 15.6 1,409 13.8 Injection drug use 5 1.3 236 2.3 Male-to-male sexual contact and injection drug use <5	40-49	48	12.9	2,080	20.4
HIV Transmission Category (Unadjusted) Male-to-male sexual contact 250 67.2 6,232 61.0 Heterosexual contact¹ 58 15.6 1,409 13.8 Injection drug use 5 1.3 236 2.3 Male-to-male sexual contact and injection drug use <5	50-59	39	10.5	2,516	24.6
Male-to-male sexual contact 250 67.2 6,232 61.0 Heterosexual contact¹ 58 15.6 1,409 13.8 Injection drug use 5 1.3 236 2.3 Male-to-male sexual contact and injection drug use <5	60+	22	5.9	1,973	19.3
Heterosexual contact¹ 58 15.6 1,409 13.8 Injection drug use 5 1.3 236 2.3 Male-to-male sexual contact and injection drug use <5 299 2.9 Adult Other² 0 0.0 77 0.8 Perinatal/other pediatric³ <5 10 0.1 No risk identified or reported (NIR/NRR) 57 15.3 1,956 19.1 HIV Transmission Category (Adjusted)⁴	HIV Transmission Category (Unadjusted)				
Injection drug use 5	Male-to-male sexual contact	250	67.2	6,232	61.0
Male-to-male sexual contact and injection drug use <5 299 2.9 Adult Other² 0 0.0 77 0.8 Perinatal/other pediatric³ <5	Heterosexual contact ¹	58	15.6	1,409	13.8
Adult Other² 0 0.0 77 0.8 Perinatal/other pediatric³ <5	Injection drug use	5	1.3	236	2.3
Perinatal/other pediatric³ <5 10 0.1 No risk identified or reported (NIR/NRR) 57 15.3 1,956 19.1 HIV Transmission Category (Adjusted)⁴ Male-to-male sexual contact 285 76.6 7,188 70.3 Heterosexual contact¹ 74 19.9 2,087 20.4 Injection drug use 8 2.1 372 3.6 Male-to-male sexual contact and injection drug use <5	Male-to-male sexual contact and injection drug use	<5		299	2.9
No risk identified or reported (NIR/NRR) 57 15.3 1,956 19.1 HIV Transmission Category (Adjusted) ⁴ Male-to-male sexual contact 285 76.6 7,188 70.3 Heterosexual contact ¹ 74 19.9 2,087 20.4 Injection drug use 8 2.1 372 3.6 Male-to-male sexual contact and injection drug use <5	Adult Other ²	0	0.0	77	0.8
HIV Transmission Category (Adjusted) ⁴ Male-to-male sexual contact 285 76.6 7,188 70.3 Heterosexual contact ¹ 74 19.9 2,087 20.4 Injection drug use 8 2.1 372 3.6 Male-to-male sexual contact and injection drug use <5	Perinatal/other pediatric ³	<5		10	0.1
Male-to-male sexual contact 285 76.6 7,188 70.3 Heterosexual contact¹ 74 19.9 2,087 20.4 Injection drug use 8 2.1 372 3.6 Male-to-male sexual contact and injection drug use <5	No risk identified or reported (NIR/NRR)	57	15.3	1,956	19.1
Heterosexual contact¹ 74 19.9 2,087 20.4 Injection drug use 8 2.1 372 3.6 Male-to-male sexual contact and injection drug use <5	HIV Transmission Category (Adjusted) ⁴				
Injection drug use 8 2.1 372 3.6 Male-to-male sexual contact and injection drug use <5 373 3.7 Adult Other ² 0 0.0 77 0.8 Perinatal/other pediatric ³ <5 10 0.1	Male-to-male sexual contact	285	76.6	7,188	70.3
Male-to-male sexual contact and injection drug use <5 373 3.7 Adult Other ² 0 0.0 77 0.8 Perinatal/other pediatric ³ <5 10 0.1	Heterosexual contact ¹	74	19.9	2,087	20.4
Adult Other ² 0 0.0 77 0.8 Perinatal/other pediatric ³ $<$ 5 10 0.1	Injection drug use	8	2.1	372	3.6
Perinatal/other pediatric ³ <5 10 0.1	Male-to-male sexual contact and injection drug use	<5		373	3.7
	Adult Other ²	0	0.0	77	0.8
No risk identified or reported (NIR/NRR) <5 112 1.1	Perinatal/other pediatric ³	<5		10	0.1
	No risk identified or reported (NIR/NRR)	<5		112	1.1

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 17. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 4 (LAGRANGE), GEORGIA, 2022

	HIV Diagn	ioses	PWH	
	N	%*	N	%*
Total	155	100.0	2,932	100.0
Gender Identity				
Cisgender Male	123	79.4	2,127	72.5
Cisgender Female	27	17.4	770	26.3
Transgender Persons/Additional Gender Identity	5	3.2	33	1.1
Race/Ethnicity				
Black or African American/non-Hispanic	120	77.4	1,952	66.6
White/non-Hispanic	21	13.5	566	19.3
Hispanic/Latino, Any Race	11	7.1	193	6.6
Asian	0	0.0	5	0.2
American Indian/Alaska Native	<5		<5	
Native Hawaiian/Pacific Islander	0	0.0	0	0.0
Multiple Races	0	0.0	183	6.2
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	0	0.0	5	0.2
13-19	7	4.5	18	0.6
20-29	64	41.3	337	11.5
30-39	43	27.7	670	22.9
40-49	21	13.5	602	20.5
50-59	13	8.4	731	24.9
60+	7	4.5	568	19.4
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	73	47.1	1,367	46.6
Heterosexual contact ¹	32	20.6	573	19.5
Injection drug use	0	0.0	118	4.0
Male-to-male sexual contact and injection drug use	<5		97	3.3
Adult Other ²	0	0.0	31	1.1
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	47	30.3	742	25.3
HIV Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	104	67.4	1,714	58.5
Heterosexual contact ¹	43	27.5	855	29.2
Injection drug use	<5		173	5.9
Male-to-male sexual contact and injection drug use	<5		121	4.1
Adult Other ²	0	0.0	31	1.1
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	<5		33	1.1
	-			

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 18. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 5-1 (DUBLIN), GEORGIA, 2022

	HIV Dia	gnoses	PV	VH
	N	%*	N	%*
Total	24	100.0	699	100.0
Gender Identity				
Cisgender Male	21	87.5	474	67.8
Cisgender Female	<5		216	30.9
Transgender Persons/Additional Gender Identity	0	0.0	9	1.3
Race/Ethnicity				
Black or African American/non-Hispanic	17	70.8	484	69.2
White/non-Hispanic	7	29.2	83	11.9
Hispanic/Latino, Any Race	0	0.0	63	9.0
Asian	0	0.0	0	0.0
American Indian/Alaska Native	0	0.0	0	0.0
Native Hawaiian/Pacific Islander	0	0.0	0	0.0
Multiple Races	0	0.0	61	8.7
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	0	0.0	0	0.0
13-19	<5		<5	
20-29	11	45.8	63	9.0
30-39	5	20.8	122	17.5
40-49	<5		149	21.3
50-59	<5		192	27.5
60+	<5		170	24.3
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	8	33.3	193	27.6
Heterosexual contact ¹	<5		160	22.9
Injection drug use	<5		52	7.4
Male-to-male sexual contact and injection drug use	<5		20	2.9
Adult Other ²	0	0.0	5	0.7
Perinatal/other pediatric ³	0	0.0	0	0.0
No risk identified or reported (NIR/NRR)	7	29.2	269	38.5
HIV Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	13	52.1	317	45.4
Heterosexual contact ¹	6	24.6	264	37.8
Injection drug use	<5		76	10.8
Male-to-male sexual contact and injection drug use	<5		29	4.1
Adult Other ²	0	0.0	5	0.7
Perinatal/other pediatric ³	0	0.0	0	0.0
No risk identified or reported (NIR/NRR)	0	0.0	8	1.1

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion. 3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 19. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 5-2 (MACON), GEORGIA, 2022

Total N %* N %* Cender Identity 126 100.0 2,591 100.0 Cisgender Male 86 68.3 1,761 68.0 Cisgender Female 38 30.2 789 30.5 Transgender Persons/Additional Gender Identity <5 39 1.5 Race/Ethnicity 88 77.8 1,935 74.7 White/non-Hispanic 98 77.8 1,935 74.7 White/non-Hispanic 98 77.8 1,935 74.7 Hispanic/Latino, Any Race 5 4.0 111 4.3 Asian 0 0.0 <5 American Indian/Alaska Native 0 0.0 <5 American Indian/Pacific Islander 0 0.0 <5 American Indian/Pacific Islander 0 0.0 <5 Age Group 4 4 0 0.0 5 0.0 421 <t< th=""><th></th><th>HIV Diag</th><th>gnoses</th><th>PWH</th><th></th></t<>		HIV Diag	gnoses	PWH	
Cisgender Male 86 68.3 1,761 68.0 Cisgender Female 38 30.2 789 30.5 Transgender Persons/Additional Gender Identity 45 39 1.5 Race/Ethnicity 87 7.8 1,935 74.7 White/non-Hispanic 98 77.8 1,935 74.7 White/non-Hispanic 21 16.7 376 14.5 Hispanic/Latino, Any Race 5 4.0 111 4.3 Asian 0 0.0 45 American Indian/Alaska Native 0 0.0 0 0.0 Multiple Races 45 145 5.6 Age Group (at diagnosis for diagnosed, current for PWH) 413 9 7.1 17 0.7 20-29 40 31.7 274 10.6 30-39 29 23.0 613 23.7 40-49 24 19.0 509 19.6 50-59 17 13.5 614 23.7 60+4 49 50-59 17 13.5 614 23.7 60+4 10-4 13.5 614 23.7 60+4 14 14 15 15 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 55 43.7 1,036 40.0 Heterosexual contact 55 86 3.3 Adult Other 0 0.0 0 5 No risk identified or reported (NiR/NR) 29 23.0 780 30.1 HIV Transmission Category (Adjusted) Male-to-male sexual contact 51 40.3 899 34.7 Nale-to-male sexual contact 51 40.3 899 34.7 Nal		N	%*	N	%*
Cisgender Male 86 68.3 1,761 68.0 Cisgender Female 38 30.2 789 30.5 Transgender Persons/Additional Gender Identity <5	Total	126	100.0	2,591	100.0
Cisgender Female 38 30.2 789 30.5 Transgender Persons/Additional Gender Identity <5	Gender Identity				
Transgender Persons/Additional Gender Identity <5 — 39 1.5 Race/Ethnicity 98 77.8 1,935 74.7 White/non-Hispanic 21 16.7 376 14.5 Hispanic/Latino, Any Race 5 4.0 111 4.3 Asian 0 0.0 <5 — American Indian/Alaska Native 0 0.0 0 0 Multiple Races <5 — 145 5.6 Age Group (at diagnosis for diagnosed, current for PWH) 5.6 —	Cisgender Male	86	68.3	1,761	68.0
Race/Ethnicity Slack or African American/non-Hispanic 98 77.8 1,935 74.7 74.7 74.5 11.6 73.76 14.5 11.5 14.5	Cisgender Female	38	30.2	789	30.5
Black or African American/non-Hispanic 98 77.8 1,935 74.7	Transgender Persons/Additional Gender Identity	<5		39	1.5
White/non-Hispanic 21 16.7 376 14.5 Hispanic/Latino, Any Race 5 4.0 111 4.3 Asian 0 0.0 <5	Race/Ethnicity				
Hispanic/Latino, Any Race	Black or African American/non-Hispanic	98	77.8	1,935	74.7
Asian 0 0.0 <5 American Indian/Alaska Native 0 0.0 <5	White/non-Hispanic	21	16.7	376	14.5
American Indian/Alaska Native 0 0.0 <5 Native Hawaiian/Pacific Islander 0 0.0 0 0 Multiple Races <5	Hispanic/Latino, Any Race	5	4.0	111	4.3
Native Hawaiian/Pacific Islander 0 0.0 0 0.0 Multiple Races <5 145 5.6 Age Group (at diagnosis for diagnosed, current for PWH) 3 3 3 3 2 2 <13	Asian	0	0.0	<5	
Multiple Races <5	American Indian/Alaska Native	0	0.0	<5	
Age Group (at diagnosis for diagnosed, current for PWH) <13	Native Hawaiian/Pacific Islander	0	0.0	0	0.0
Cat diagnosis for diagnosed, current for PWH) Cat Cat	Multiple Races	<5		145	5.6
\$\colon 13-19\$ 0 0.0 5 0.2 13-19 9 7.1 17 0.7 20-29 40 31.7 274 10.6 30-39 29 23.0 613 23.7 40-49 24 19.0 509 19.6 50-59 17 13.5 614 23.7 60+ 7 5.6 559 21.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 55 43.7 1,036 40.0 Heterosexual contact ¹ 37 29.4 557 21.5 Injection drug use <5	Age Group				
13-19 9 7.1 17 0.7 20-29 40 31.7 274 10.6 30-39 29 23.0 613 23.7 40-49 24 19.0 509 19.6 50-59 17 13.5 614 23.7 60+ 7 5.6 559 21.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 55 43.7 1,036 40.0 Heterosexual contact ¹ 37 29.4 557 21.5 Injection drug use <5	(at diagnosis for diagnosed, current for PWH)				
20-29 40 31.7 274 10.6 30-39 29 23.0 613 23.7 40-49 24 19.0 509 19.6 50-59 17 13.5 614 23.7 60+ 7 5.6 559 21.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 55 43.7 1,036 40.0 Heterosexual contact ¹ 37 29.4 557 21.5 Injection drug use <5	<13	0	0.0	5	0.2
30-39 29 23.0 613 23.7 40-49 24 19.0 509 19.6 50-59 17 13.5 614 23.7 60+ 7 5.6 559 21.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 55 43.7 1,036 40.0 Heterosexual contact ¹ 37 29.4 557 21.5 Injection drug use <5	13-19	9	7.1	17	0.7
40-49 24 19.0 509 19.6 50-59 17 13.5 614 23.7 60+ 7 5.6 559 21.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 55 43.7 1,036 40.0 Heterosexual contact ¹ 37 29.4 557 21.5 Injection drug use <5	20-29	40	31.7	274	10.6
50-59 17 13.5 614 23.7 60+ 7 5.6 559 21.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 55 43.7 1,036 40.0 Heterosexual contact ¹ 37 29.4 557 21.5 Injection drug use <5	30-39	29	23.0	613	23.7
Total Content	40-49	24	19.0	509	19.6
HIV Transmission Category (Unadjusted) Male-to-male sexual contact 55 43.7 1,036 40.0 Heterosexual contact¹ 37 29.4 557 21.5 Injection drug use <5	50-59	17	13.5	614	23.7
Male-to-male sexual contact 55 43.7 1,036 40.0 Heterosexual contact¹ 37 29.4 557 21.5 Injection drug use <5	60+	7	5.6	559	21.6
Heterosexual contact¹ 37 29.4 557 21.5 Injection drug use <5 107 4.1 Male-to-male sexual contact and injection drug use <5 86 3.3 Adult Other² 0 0.0 21 0.8 Perinatal/other pediatric³ 0 0.0 <5 No risk identified or reported (NIR/NRR) 29 23.0 780 30.1 HIV Transmission Category (Adjusted)⁴	HIV Transmission Category (Unadjusted)				
Injection drug use	Male-to-male sexual contact	55	43.7	1,036	40.0
Male-to-male sexual contact and injection drug use <5	Heterosexual contact ¹	37	29.4	557	21.5
Adult Other² 0 0.0 21 0.8 Perinatal/other pediatric³ 0 0.0 <5	Injection drug use	<5		107	4.1
Perinatal/other pediatric³ 0 0.0 <5 No risk identified or reported (NIR/NRR) 29 23.0 780 30.1 HIV Transmission Category (Adjusted)⁴ Male-to-male sexual contact 67 53.2 1,365 52.7 Heterosexual contact¹ 51 40.3 899 34.7 Injection drug use <5	Male-to-male sexual contact and injection drug use	<5		86	3.3
No risk identified or reported (NIR/NRR) 29 23.0 780 30.1 HIV Transmission Category (Adjusted) ⁴ Male-to-male sexual contact 67 53.2 1,365 52.7 Heterosexual contact ¹ 51 40.3 899 34.7 Injection drug use <5	Adult Other ²	0	0.0	21	0.8
HIV Transmission Category (Adjusted) ⁴ Male-to-male sexual contact 67 53.2 1,365 52.7 Heterosexual contact ¹ 51 40.3 899 34.7 Injection drug use <5	Perinatal/other pediatric ³	0	0.0	<5	
Male-to-male sexual contact 67 53.2 1,365 52.7 Heterosexual contact¹ 51 40.3 899 34.7 Injection drug use <5	No risk identified or reported (NIR/NRR)	29	23.0	780	30.1
Heterosexual contact¹ 51 40.3 899 34.7 Injection drug use <5	HIV Transmission Category (Adjusted) ⁴				
Injection drug use <5 172 6.7 Male-to-male sexual contact and injection drug use <5 108 4.2 Adult Other ² 0 0.0 21 0.8 Perinatal/other pediatric ³ 0 0.0 <5	Male-to-male sexual contact	67	53.2	1,365	52.7
Male-to-male sexual contact and injection drug use <5 108 4.2 Adult Other ² 0 0.0 21 0.8 Perinatal/other pediatric ³ 0 0.0 <5	Heterosexual contact ¹	51	40.3	899	34.7
Adult Other ² 0 0.0 21 0.8 Perinatal/other pediatric ³ 0 0.0 $<$ 5	Injection drug use	<5		172	6.7
Perinatal/other pediatric ³ 0 0.0 <5	Male-to-male sexual contact and injection drug use	<5		108	4.2
	Adult Other ²	0	0.0	21	0.8
No risk identified or reported (NIR/NRR) <5 22 0.8	Perinatal/other pediatric ³	0	0.0	<5	
	No risk identified or reported (NIR/NRR)	<5		22	0.8

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases<13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 20. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 6 (AUGUSTA), GEORGIA, 2022

	HIV Dia	gnoses	P\	VH
	N	%*	N	%*
Total	100	100.0	2,418	100.0
Gender Identity				
Cisgender Male	70	70.0	1,622	67.1
Cisgender Female	28	28.0	750	31.0
Transgender Persons/Additional Gender Identity	<5		46	1.9
Race/Ethnicity				
Black or African American/non-Hispanic	77	77.0	1,803	74.6
White/non-Hispanic	15	15.0	391	16.2
Hispanic/Latino, Any Race	5	5.0	89	3.7
Asian	<5		5	0.2
American Indian/Alaska Native	0	0.0	0	0.0
Native Hawaiian/Pacific Islander	0	0.0	<5	
Multiple Races	0	0.0	109	4.5
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	0	0.0	<5	
13-19	<5		23	1.0
20-29	48	48.0	301	12.4
30-39	22	22.0	503	20.8
40-49	6	6.0	352	14.6
50-59	16	16.0	587	24.3
60+	6	6.0	649	26.8
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	49	49.0	993	41.1
Heterosexual contact ¹	21	21.0	535	22.1
Injection drug use	<5		143	5.9
Male-to-male sexual contact and injection drug use	<5		90	3.7
Adult Other ²	0	0.0	77	3.2
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	27	27.0	577	23.9
HIV Transmission Category (Adjusted)⁴				
Male-to-male sexual contact	59	59.1	1,204	49.8
Heterosexual contact ¹	34	33.9	812	33.6
Injection drug use	<5		197	8.2
Male-to-male sexual contact and injection drug use	<5		104	4.3
Adult Other ²	0	0.0	77	3.2
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	<5		20	0.8
	.5		-0	0.0

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 21. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 7 (COLUMBUS), GEORGIA, 2022

N
Cisgender Male
Cisgender Male 44 63.8 1,303 66.4 Cisgender Female 25 36.2 636 32.4 Transgender Persons/Additional Gender Identity 0 0.0 22 1.1 Race/Ethnicity Black or African American/non-Hispanic 54 78.3 1,434 73.1 White/non-Hispanic 9 13.0 235 12.0 Hispanic/Latino, Any Race 5 7.2 139 7.1 Asian 0 0.0 <5
Cisgender Female 25 36.2 636 32.4 Transgender Persons/Additional Gender Identity 0 0.0 22 1.1 Race/Ethnicity Black or African American/non-Hispanic 54 78.3 1,434 73.1 White/non-Hispanic 9 13.0 235 12.0 Hispanic/Latino, Any Race 5 7.2 139 7.1 Asian 0 0.0 <5
Transgender Persons/Additional Gender Identity 0 0.0 22 1.1 Race/Ethnicity Black or African American/non-Hispanic 54 78.3 1,434 73.1 White/non-Hispanic 9 13.0 235 12.0 Hispanic/Latino, Any Race 5 7.2 139 7.1 Asian 0 0.0 <5
Race/Ethnicity Black or African American/non-Hispanic 54 78.3 1,434 73.1 White/non-Hispanic 9 13.0 235 12.0 Hispanic/Latino, Any Race 5 7.2 139 7.1 Asian 0 0.0 <5
Black or African American/non-Hispanic 54 78.3 1,434 73.1 White/non-Hispanic 9 13.0 235 12.0 13.0 12.0 13.0 235 12.0 14.0 13.0
White/non-Hispanic 9 13.0 235 12.0 Hispanic/Latino, Any Race 5 7.2 139 7.1 Asian 0 0.0 <5
Hispanic/Latino, Any Race
Asian 0 0.0 0.0 <5 American Indian/Alaska Native 0 0.0 0.0 <5 Native Hawaiian/Pacific Islander 0 0.0 0.0 0 0.0 Multiple Races <5 102 5.2 Age Group (at diagnosis for diagnosed, current for PWH) <13 0 0.0 <5 13-19 5 7.2 7 0.4 20-29 30 43.5 204 10.4 30-39 13 18.8 407 20.7 40-49 8 11.6 386 19.7 50-59 8 11.6 386 19.7 50-59 8 11.6 492 25.1 60+ 5 7.2 464 23.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 24 34.8 679 34.6 Heterosexual contact 27 39.1 528 26.9 Injection drug use <5 96 4.9 Male-to-male sexual contact and injection drug use <5 96 4.9 Male-to-male sexual contact and injection drug use <5 47 2.4
American Indian/Alaska Native 0 0.0 <5
Native Hawaiian/Pacific Islander 0 0.0 0 0.0 Multiple Races <5 102 5.2 Age Group (at diagnosis for diagnosed, current for PWH) <13
Multiple Races <5 102 5.2 Age Group (at diagnosis for diagnosed, current for PWH) <13
Age Group (at diagnosis for diagnosed, current for PWH) <13
(at diagnosis for diagnosed, current for PWH) <13
<13
13-19 5 7.2 7 0.4 20-29 30 43.5 204 10.4 30-39 13 18.8 407 20.7 40-49 8 11.6 386 19.7 50-59 8 11.6 492 25.1 60+ 5 7.2 464 23.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 24 34.8 679 34.6 Heterosexual contact ¹ 27 39.1 528 26.9 Injection drug use <5
20-29 30 43.5 204 10.4 30-39 13 18.8 407 20.7 40-49 8 11.6 386 19.7 50-59 8 11.6 492 25.1 60+ 5 7.2 464 23.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 24 34.8 679 34.6 Heterosexual contact ¹ 27 39.1 528 26.9 Injection drug use <5
30-39 13 18.8 407 20.7 40-49 8 11.6 386 19.7 50-59 8 11.6 492 25.1 60+ 5 7.2 464 23.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 24 34.8 679 34.6 Heterosexual contact ¹ 27 39.1 528 26.9 Injection drug use <5
40-49 8 11.6 386 19.7 50-59 8 11.6 492 25.1 60+ 5 7.2 464 23.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 24 34.8 679 34.6 Heterosexual contact ¹ 27 39.1 528 26.9 Injection drug use <5
50-59 8 11.6 492 25.1 60+ 5 7.2 464 23.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 24 34.8 679 34.6 Heterosexual contact ¹ 27 39.1 528 26.9 Injection drug use <5
60+ 5 7.2 464 23.6 HIV Transmission Category (Unadjusted) Male-to-male sexual contact 24 34.8 679 34.6 Heterosexual contact¹ 27 39.1 528 26.9 Injection drug use <5
HIV Transmission Category (Unadjusted) Male-to-male sexual contact 24 34.8 679 34.6 Heterosexual contact¹ 27 39.1 528 26.9 Injection drug use <5
Male-to-male sexual contact2434.867934.6Heterosexual contact 1 2739.152826.9Injection drug use<5
Heterosexual contact 1 2739.152826.9Injection drug use<5
Injection drug use <5 96 4.9 Male-to-male sexual contact and injection drug use <5 47 2.4
Male-to-male sexual contact and injection drug use <5 47 2.4
· · · · · · · · · · · · · · · · · · ·
Adult Other ² 0 0.0 18 0.9
Perinatal/other pediatric ³ 0 0.0 <5
No risk identified or reported (NIR/NRR) 14 20.3 592 30.2
HIV Transmission Category (Adjusted) ⁴
Male-to-male sexual contact 31 45.4 922 47.0
Heterosexual contact ¹ 33 47.5 771 39.3
Injection drug use <5 135 6.9
Male-to-male sexual contact and injection drug use <5 63 3.2
Adult Other ² 0 0.0 18 0.9
Perinatal/other pediatric ³ 0 0.0 <5
No risk identified or reported (NIR/NRR) 0 0.0 51 2.6

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 22. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 8-1 (VALDOSTA), GEORGIA, 2022

	HIV Diag	noses	PWH	
	N	%*	N	%*
Total	68	100.0	1,294	100.0
Gender Identity				
Cisgender Male	41	60.3	799	61.7
Cisgender Female	26	38.2	485	37.5
Transgender Persons/Additional Gender Identity	<5		10	0.8
Race/Ethnicity				
Black or African American/non-Hispanic	51	75.0	885	68.4
White/non-Hispanic	14	20.6	212	16.4
Hispanic/Latino, Any Race	<5		104	8.0
Asian	0	0.0	<5	
American Indian/Alaska Native	0	0.0	0	0.0
Native Hawaiian/Pacific Islander	0	0.0	0	0.0
Multiple Races	0	0.0	80	6.2
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	0	0.0	<5	
13-19	6	8.8	6	0.5
20-29	21	30.9	132	10.2
30-39	11	16.2	224	17.3
40-49	8	11.8	277	21.4
50-59	13	19.1	342	26.4
60+	9	13.2	312	24.1
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	26	38.2	412	31.8
Heterosexual contact ¹	25	36.8	448	34.6
Injection drug use	0	0.0	59	4.6
Male-to-male sexual contact and injection drug use	0	0.0	37	2.9
Adult Other ²	0	0.0	12	0.9
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	17	25.0	325	25.1
HIV Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	33	47.9	531	41.0
Heterosexual contact ¹	35	50.9	610	47.1
Injection drug use	<5		85	6.6
Male-to-male sexual contact and injection drug use	<5		45	3.5
Adult Other ²	0	0.0	12	0.9
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	0	0.0	10	0.8
No risk facilities of reported (Mily Mill)	U	0.0	10	0.0

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 23. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 8-2 (ALBANY), GEORGIA, 2022

	HIV Diagnoses		PWH	
	N	%*	N	%*
Total	92	100.0	1,906	100.0
Gender Identity				
Cisgender Male	57	62.0	1,198	62.9
Cisgender Female	34	37.0	688	36.1
Transgender Persons/Additional Gender Identity	<5		20	1.0
Race/Ethnicity				
Black or African American/non-Hispanic	63	68.5	1,488	78.1
White/non-Hispanic	18	19.6	203	10.7
Hispanic/Latino, Any Race	6	6.5	86	4.5
Asian	0	0.0	<5	
American Indian/Alaska Native	0	0.0	<5	
Native Hawaiian/Pacific Islander	0	0.0	0	0.0
Multiple Races	<5		115	6.0
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	0	0.0	<5	
13-19	<5		8	0.4
20-29	29	31.5	214	11.2
30-39	27	29.3	395	20.7
40-49	16	17.4	403	21.1
50-59	10	10.9	435	22.8
60+	9	9.8	448	23.5
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	24	26.1	675	35.4
Heterosexual contact ¹	33	35.9	468	24.6
Injection drug use	<5		77	4.0
Male-to-male sexual contact and injection drug use	<5		46	2.4
Adult Other ²	0	0.0	19	1.0
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	31	33.7	619	32.5
HIV Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	43	47.0	888	46.6
Heterosexual contact ¹	42	45.2	795	41.7
Injection drug use	<5		129	6.8
Male-to-male sexual contact and injection drug use	<5		62	3.2
Adult Other ²	0	0.0	19	1.0
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	<5		11	0.6

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 24. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 9-1 (SAVANNAH), GEORGIA, 2022

	HIV Diagnoses		PWH	
	N	%*	N	%*
Total	105	100.0	2,977	100.0
Gender Identity				
Cisgender Male	84	80.0	2,020	67.9
Cisgender Female	20	19.0	917	30.8
Transgender Persons/Additional Gender Identity	<5		39	1.3
Race/Ethnicity				
Black or African American/non-Hispanic	61	58.1	1,928	64.8
White/non-Hispanic	24	22.9	590	19.8
Hispanic/Latino, Any Race	13	12.4	223	7.5
Asian	0	0.0	9	0.3
American Indian/Alaska Native	0	0.0	<5	
Native Hawaiian/Pacific Islander	0	0.0	<5	
Multiple Races	5	4.8	187	6.3
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	0	0.0	<5	
13-19	11	10.5	18	0.6
20-29	40	38.1	321	10.8
30-39	27	25.7	664	22.3
40-49	8	7.6	500	16.8
50-59	12	11.4	742	24.9
60+	7	6.7	728	24.5
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	54	51.4	1,216	40.8
Heterosexual contact ¹	28	26.7	599	20.1
Injection drug use	0	0.0	155	5.2
Male-to-male sexual contact and injection drug use	<5		86	2.9
Adult Other ²	<5		39	1.3
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	20	19.0	879	29.5
HIV Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	66	62.6	1,550	52.1
Heterosexual contact ¹	33	31.1	1,008	33.9
Injection drug use	<5		230	7.7
Male-to-male sexual contact and injection drug use	<5		108	3.6
Adult Other ²	<5		39	1.3
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	<5		39	1.3

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 25. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 9-2 (WAYCROSS), GEORGIA, 2022

	HIV Diag	HIV Diagnoses		'H
	N	%*	N	%*
Total	82	100.0	1,369	100.0
Gender Identity				
Cisgender Male	59	72.0	909	66.4
Cisgender Female	21	25.6	437	31.9
Transgender Persons/Additional Gender Identity	<5		23	1.7
Race/Ethnicity				
Black or African American/non-Hispanic	49	59.8	811	59.2
White/non-Hispanic	19	23.2	286	20.9
Hispanic/Latino, Any Race	8	9.8	142	10.4
Asian	0	0.0	<5	
American Indian/Alaska Native	<5		<5	
Native Hawaiian/Pacific Islander	0	0.0	0	0.0
Multiple Races	<5		96	7.0
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	0	0.0	0	0.0
13-19	5	6.1	<5	
20-29	29	35.4	144	10.5
30-39	20	24.4	312	22.8
40-49	16	19.5	276	20.2
50-59	8	9.8	346	25.3
60+	<5		288	21.0
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	34	41.5	495	36.2
Heterosexual contact ¹	28	34.1	332	24.3
Injection drug use	<5		65	4.7
Male-to-male sexual contact and injection drug use	<5		47	3.4
Adult Other ²	0	0.0	14	1.0
Perinatal/other pediatric ³	0	0.0	0	0.0
No risk identified or reported (NIR/NRR)	17	20.7	416	30.4
HIV Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	41	50.1	656	47.9
Heterosexual contact ¹	36	43.3	515	37.6
Injection drug use	<5		99	7.2
Male-to-male sexual contact and injection drug use	<5		57	4.1
Adult Other ²	0	0.0	14	1.0
Perinatal/other pediatric ³	0	0.0	0	0.0
No risk identified or reported (NIR/NRR)	<5		29	2.1

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age \geq 13; hemophilia, blood transfusion. 3. Perinatal/other pediatric: cases <13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

TABLE 26. HIV DIAGNOSES AND PEOPLE WITH HIV, DISTRICT 10 (ATHENS), GEORGIA, 2022

	HIV Dia	HIV Diagnoses		WH
	N	%*	N	%*
Total	64	100.0	1,189	100.0
Gender Identity				
Cisgender Male	47	73.4	800	67.3
Cisgender Female	17	26.6	367	30.9
Transgender Persons/Additional Gender Identity	0	0.0	21	1.8
Race/Ethnicity				
Black or African American/non-Hispanic	30	46.9	648	54.5
White/non-Hispanic	23	35.9	338	28.4
Hispanic/Latino, Any Race	6	9.4	121	10.2
Asian	<5		6	0.5
American Indian/Alaska Native	0	0.0	0	0.0
Native Hawaiian/Pacific Islander	0	0.0	0	0.0
Multiple Races	<5		65	5.5
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	0	0.0	<5	
13-19	6	9.4	11	0.9
20-29	20	31.3	129	10.8
30-39	20	31.3	274	23.0
40-49	<5		244	20.5
50-59	6	9.4	266	22.4
60+	9	14.1	263	22.1
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	33	51.6	499	42.0
Heterosexual contact ¹	18	28.1	256	21.5
Injection drug use	<5		62	5.2
Male-to-male sexual contact and injection drug use	0	0.0	35	2.9
Adult Other ²	<5		13	1.1
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	11	17.2	322	27.1
HIV Transmission Category (Adjusted) ⁴				
Male-to-male sexual contact	37	57.0	635	53.4
Heterosexual contact ¹	24	36.9	398	33.4
Injection drug use	<5		87	7.3
Male-to-male sexual contact and injection drug use	<5		43	3.6
Adult Other ²	<5		13	1.1
Perinatal/other pediatric ³	0	0.0	<5	
No risk identified or reported (NIR/NRR)	<5		11	0.9

^{*} Percentages may not add up to 100% due to rounding 1. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion.3. Perinatal/other pediatric: cases<13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

HIV DIAGNOSES AND PEOPLE WITH HIV, ATLANTA MSA

TABLE 27. HIV DIAGNOSES AND PEOPLE WITH HIV, ATLANTA METROPOLITAN STATISTICAL AREA (MSA)¹, GEORGIA, 2022

	HIV Diagi	HIV Diagnoses		
	N	%*	N	%*
Total	1,770	100.0	45,089	100.0
Gender Identity				
Cisgender Male	1,438	81.2	35,480	78.7
Cisgender Female	289	16.3	8,817	19.6
Transgender Persons/Additional Gender Identity	43	2.4	755	1.7
Race/Ethnicity				
Black or African American/non-Hispanic	1,208	68.2	31,045	68.9
White/non-Hispanic	205	11.6	6,730	14.9
Hispanic/Latino, Any Race	277	15.6	4,038	9.0
Asian	17	1.0	288	0.6
American Indian/Alaska Native	<5		18	0.0
Native Hawaiian/Pacific Islander	0	0.0	14	0.0
Multiple Races	41	2.3	2,430	5.4
Age Group				
(at diagnosis for diagnosed, current for PWH)				
<13	<5		50	0.1
13-19	85	4.8	181	0.4
20-29	664	37.5	4,727	10.5
30-39	538	30.4	11,696	25.9
40-49	232	13.1	9,319	20.7
50-59	165	9.3	10,794	23.9
60+	83	4.7	8,314	18.4
HIV Transmission Category (Unadjusted)				
Male-to-male sexual contact	1,087	61.4	26,359	58.5
Heterosexual contact ²	335	18.9	6,591	14.6
Injection drug use	28	1.6	1,393	3.1
Male-to-male sexual contact and injection drug use	13	0.7	1,470	3.3
Adult Other ³	0	0.0	361	0.8
Perinatal/other pediatric ⁴	<5		47	0.1
No risk identified or reported (NIR/NRR)	304	17.2	8,868	19.7
HIV Transmission Category (Adjusted) ⁵				
Male-to-male sexual contact	1,272	71.9	30,680	68.0
Heterosexual contact ²	416	23.5	9,720	21.6
Injection drug use	40	2.3	1,968	4.4
Male-to-male sexual contact and injection drug use	20	1.2	1,785	4.0
Adult Other ³	0	0.0	361	0.8
Perinatal/other pediatric ⁴	<5		47	0.1
No risk identified or reported (NIR/NRR)	19	1.1	528	1.2
. , , , ,				

^{*}Percents may not add up to 100 due to rounding. 1. Atlanta Metropolitan Statistical Area (MSA) counties consist of: Barrow, Bartow, Butts, Carroll, Cherokee, Clayton, Cobb, Coweta, Dawson, DeKalb, Douglas, Fayette, Forsyth, Fulton, Gwinnett, Haralson, Heard, Henry, Jasper, Lamar, Meriwether, Morgan, Newton, Paulding, Pickens, Pike, Rockdale, Spalding, Walton. 2. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 3. Includes perinatal exposure age ≥13, hemophilia, blood transfusion. 4. Perinatal/other pediatric: cases <13 years born to a mother who is HIV-positive, and cases <13 with missing risk. 5. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

HIV DIAGNOSES AND LATE DIAGNOSES BY PUBLIC HEALTH DISTRICT AND ATLANTA MSA

TABLE 28. HIV DIAGNOSES AND LATE DIAGNOSES BY PUBLIC HEALTH DISTRICT AND ATLANTA METROPOLITAN STATISTICAL AREA (MSA), GEORGIA, 2022

	HIV Diagn	HIV Diagnoses		Late HIV Diagnoses ¹	
	N	%*	N	%*	Row %
Public Health District					
1-1 Northwest (Rome)	71	2.8	20	3.4	28.2
1-2 North Georgia (Dalton)	27	1	10	1.7	37.0
2 North (Gainesville)	67	2.6	14	2.4	20.9
3-1 Cobb-Douglas	211	8.2	53	9	25.1
3-2 Fulton	526	20.4	111	18.8	21.1
3-3 Clayton (Jonesboro)	143	5.6	33	5.6	23.1
3-4 East Metro (Lawrenceville)	265	10.3	56	9.5	21.1
3-5 DeKalb	372	14.4	73	12.3	19.6
4 LaGrange	155	6	28	4.7	18.1
5-1 South Central (Dublin)	24	0.9	5	0.8	20.8
5-2 North Central (Macon)	126	4.9	34	5.7	27.0
6 East Central (Augusta)	100	3.9	25	4.2	25.0
7 West Central (Columbus)	69	2.7	20	3.4	29.0
8-1 South (Valdosta)	68	2.6	21	3.5	30.9
8-2 Southwest (Albany)	92	3.6	33	5.6	35.9
9-1 Coastal (Savannah)	105	4.1	21	3.5	20.0
9-2 Southeast (Waycross)	82	3.2	18	3	22.0
10 Northeast (Athens)	64	2.5	17	2.9	26.6
MSA ²					
In the Atlanta MSA	1,770	68.7	380	64.2	21.5
Not in the Atlanta MSA	805	31.3	212	35.8	26.3

^{*}Percentages may not add up to 100% due to rounding and missing data. 1. Late diagnosis: stage 3 (AIDS) diagnosis within 12 months of HIV diagnosis. Row % is percent of HIV diagnoses that were late diagnoses. 2. Atlanta Metropolitan Statistical Area (MSA) counties consist of: Barrow, Bartow, Butts, Carroll, Cherokee, Clayton, Cobb, Coweta, Dawson, DeKalb, Douglas, Fayette, Forsyth, Fulton, Gwinnett, Haralson, Heard, Henry, Jasper, Lamar, Meriwether, Morgan, Newton, Paulding, Pickens, Pike, Rockdale, Spalding, Walton.

PUBLIC HEALTH DISTRICT AND COUNTY RATES

TABLE 29. HIV DIAGNOSES AND PEOPLE WITH HIV (PWH) BY PUBLIC HEALTH DISTRICT AND COUNTY (NUMBER AND RATES PER 100,000 POPULATION), GEORGIA, 2022

	HIV Dia	gnoses	PV	VН
	N ¹	Rate/100,000 ^{2,3}	N^1	Rate/100,000 ^{2,3}
1-1 Northwest (Rome)	71	10.1	1374	195.3
Bartow Co.	18	16.0	255	226.0
Catoosa Co.	<5		76	110.4
Chattooga Co.	<5		61	244.6
Dade Co.	0	0.0	13	80.8
Floyd Co.	12	12.1	266	267.5
Gordon Co.	<5		77	130.6
Haralson Co.	<5		39	124.5
Paulding Co.	19	10.6	443	248.3
Polk Co.	8		62	141.8
Walker Co.	5		82	119.0
1-2 North Georgia (Dalton)	27	5.2	793	153.1
Cherokee Co.	15	5.3	444	157.9
Fannin Co.	0	0.0	48	186.5
Gilmer Co.	0	0.0	59	182.1
Murray Co.	0	0.0	39	96.4
Pickens Co.	6		43	123.5
Whitfield Co.	6		160	155.1
2 North (Gainesville)	67	8.6	1,117	144.2
Banks Co.	0	0.0	15	77.6
Dawson Co.	<5		37	122.8
Forsyth Co.	17	6.4	270	101.0
Franklin Co.	<5		51	211.4
Habersham Co.	<5		83	174.8
Hall Co.	29	13.6	418	196.5
Hart Co.	<5		54	200.7
Lumpkin Co.	<5		34	97.7
Rabun Co.	0	0.0	18	104.6
Stephens Co.	<5		51	190.5
Towns Co.	<5		22	169.6
Union Co.	<5		40	151.6
White Co.	<5		24	83.3
3-1 Cobb-Douglas	211	23.0	4,801	522.3
Cobb Co.	174	22.5	4,016	520.2
Douglas Co.	37	25.1	785	532.9
3-2 Fulton	526	48.9	16,975	1,579.6
Fulton Co.	526	48.9	16,975	1,579.6
3-3 Clayton (Jonesboro)	143	48.2	3,357	1,132.0
Clayton Co.	143	48.2	3,357	1,132.0
ciay ton co.				

	HIV Dia	agnoses	PI	WH
	N ¹	Rate/100,000 ^{2,3}	N^1	Rate/100,000 ^{2,3}
Gwinnett Co.	216	22.1	4,103	420.7
Newton Co.	17	14.5	457	388.5
Rockdale Co.	32	33.7	542	570.6
3-5 DeKalb	372	48.8	10,219	1,339.6
DeKalb Co.	372	48.8	10,219	1,339.6
4 LaGrange	155	17.0	2,932	320.9
Butts Co.	30	112.6	192	720.5
Carroll Co.	17	13.6	284	227.9
Coweta Co.	12	7.8	338	221.1
Fayette Co.	10		255	209.0
Heard Co.	0	0.0	14	119.4
Henry Co.	56	22.5	1,164	468.7
Lamar Co.	<5		45	231.2
Meriwether Co.	5		81	388.6
Pike Co.	<5		15	75.0
Spalding Co.	9		251	364.2
Troup Co.	10		220	313.4
Upson Co.	<5		73	259.9
5-1 South Central (Dublin)	24	16.6	699	484.1
Bleckley Co.	<5		48	391.6
Dodge Co.	<5		115	580.7
Johnson Co.	<5		60	649.2
Laurens Co.	5		187	376.6
Montgomery Co.	0	0.0	21	242.6
Pulaski Co.	0	0.0	48	480.8
Telfair Co.	<5		86	696.1
Treutlen Co.	<5		23	361.4
Wheeler Co.	<5		24	328.1
Wilcox Co.	<5		87	993.0
5-2 North Central (Macon)	126	22.8	2,591	469.8
Baldwin Co.	10		186	426.3
Bibb Co.	57	36.5	1,388	888.6
Crawford Co.	<5		28	230.6
Hancock Co.	<5		53	631.9
Houston Co.	28	16.5	494	291.2
Jasper Co.	<5		22	137.9
Jones Co.	<5 _		55	193.2
Monroe Co.	7		79	268.5
Peach Co.	9		135	472.7
Putnam Co.	<5		40	174.0
Twiggs Co.	<5		13	169.3
Washington Co.	<5		72	364.8
Wilkinson Co.	<5	10.0	26	299.5
6 East Central (Augusta)	100	19.9	2,418	480.5
Burke Co.	<5 11		98	401.8
Columbia Co.	11		259	159.5
Emanuel Co.	<5		75	327.1
Glascock Co.	0	0.0	7	365.7
Jefferson Co.	<5		56	365.7
Jenkins Co.	<5		37	425.8

	HIV Diagnoses PWH		WH	
	N^1	Rate/100,000 ^{2,3}	N^1	Rate/100,000 ^{2,3}
Lincoln Co.	<5		19	242.3
McDuffie Co.	<5		64	294.8
Richmond Co.	72	34.8	1,695	820.3
Screven Co.	<5		46	329.1
Taliaferro Co.	0	0.0	10	
Warren Co.	0	0.0	21	407.4
Wilkes Co.	<5		31	323.0
7 West Central (Columbus)	69	19.0	1,963	541.9
Chattahoochee Co.	<5		11	
Clay Co.	<5		12	421.8
Crisp Co.	5		138	700.2
Dooly Co.	<5		74	700.0
Harris Co.	<5		48	132.3
Macon Co.	<5		59	501.5
Marion Co.	<5		14	187.9
Muscogee Co.	50	24.7	1,214	599.2
Quitman Co.	0	0.0	5	
Randolph Co.	0	0.0	42	686.7
Schley Co.	<5		9	
Stewart Co. ⁴	<5		132	2839.9
Sumter Co.	<5		143	495.2
Talbot Co.	0	0.0	27	469.8
Taylor Co.	0	0.0	32	413.6
Webster Co.	<5		<5	
8-1 South (Valdosta)	68	26.0	1,294	494.1
Ben Hill Co.	0	0.0	54	316.4
Berrien Co.	5		53	291.0
Brooks Co.	<5		67	412.2
Cook Co.	<5		80	459.7
Echols Co.	0	0.0	14	379.8
Irwin Co.	<5		84	920.4
Lanier Co.	<5		31	304.8
Lowndes Co.	37	30.9	680	567.9
Tift Co.	12	29.0	183	441.9
Turner Co.	<5		48	542.9
8-2 Southwest (Albany)	92	26.5	1,906	549.3
Baker Co.	<5		6	
Calhoun Co.	<5		60	1,097.1
Colquitt Co.	17	37.1	219	478.6
Decatur Co.	6		151	521.0
Dougherty Co.	37	44.6	807	972.7
Early Co.	5		31	293.2
Grady Co.	<5		72	276.8
Lee Co.	7		77	228.9
Miller Co.	<5		17	292.8
Mitchell Co.	<5		131	620.4
Seminole Co.	<5		29	317.7
Terrell Co.	<5		50	571.2
Thomas Co.	6		177	388.5
Worth Co.	<5		79	386.8

	HIV Di	agnoses	P	WH
	N^1	Rate/100,000 ^{2,3}	N^1	Rate/100,000 ^{2,3}
9-1 Coastal (Savannah)	105	16.0	2,977	452.4
Bryan Co.	<5		58	120.3
Camden Co.	<5		104	182.4
Chatham Co.	64	21.3	1,983	658.6
Effingham Co.	10		106	153.5
Glynn Co.	15	17.6	378	444.3
Liberty Co.	8		257	377.8
Long Co.	<5		36	196.2
McIntosh Co.	<5		55	491.9
9-2 Southeast (Waycross)	82	21.8	1,369	364.3
Appling Co.	<5		50	271.3
Atkinson Co.	<5		20	244.4
Bacon Co.	<5		44	393.2
Brantley Co.	<5		25	137.5
Bulloch Co.	22	26.5	292	351.6
Candler Co.	0	0.0	24	218.2
Charlton Co.	<5		88	688.5
Clinch Co.	<5		24	360.3
Coffee Co.	9		143	331.2
Evans Co.	5		50	467.5
Jeff Davis Co.	0	0.0	31	208.2
Pierce Co.	<5		33	163.6
Tattnall Co.	9		114	473.7
Toombs Co.	10		101	376.3
Ware Co.	8		197	553.2
Wayne Co.	<5		133	430.5
10 Northeast (Athens)	64	11.5	1,189	213.2
Barrow Co.	16	17.9	161	180.3
Clarke Co.	22	16.9	478	368.0
Elbert Co.	<5		39	196.8
Greene Co.	<5		40	198.6
Jackson Co.	7		96	114.4
Madison Co.	0	0.0	45	143.0
Morgan Co.	<5		38	180.7
Oconee Co.	<5		23	52.8
Oglethorpe Co.	<5		25	161.6
Walton Co.	11		244	236.7

^{1.} Counts of 1-4 are censored. 2. Rates are not calculated when the numerator is <12. 3. Persons residing in correctional facilities are included in this report and may inflate rates in certain geographic regions where there are large numbers of HIV-positive inmates. 4. Many cases associated with a federal immigration detention facility are located in this county.

DEATHS AMONG PEOPLE WITH HIV

TABLE 30. DEATHS AMONG PEOPLE WITH HIV (PWH), GEORGIA 2022

	Deaths ¹ a	mong PWH
	N N	%*
Total	925	100.0
Gender Identity		
Cisgender Male	668	72.2
Cisgender Female	249	26.9
Transgender Persons/Additional Gender Identity	7	0.8
Race/Ethnicity		
Black or African American/non-Hispanic	636	68.8
White/non-Hispanic	178	19.2
Hispanic/Latino, Any Race	51	5.5
Asian	1	0.1
American Indian/Alaska Native	0	0.0
Native Hawaiian/Pacific Islander	0	0.0
Multiple Races	59	6.4
Age Group (at time of death)		
<13	0	0.0
13-19	0	0.0
20-29	33	3.6
30-39	116	12.5
40-49	150	16.2
50-59	261	28.2
60+	365	39.5
HIV Transmission Category (Unadjusted)		
Male-to-male sexual contact	351	38.0
Heterosexual contact ²	181	19.6
Injection drug use	60	6.5
Male-to-male sexual contact and injection drug use	58	6.3
Adult Other ³	5	0.5
Perinatal/other pediatric ⁴	0	0.0
No risk identified or reported (NIR/NRR)	270	29.2
HIV Transmission Category (Adjusted) ⁵	467	50.5
Male-to-male sexual contact	467	50.5
Heterosexual contact ²	299	32.4
Injection drug use	85	9.2
Male-to-male sexual contact and injection drug use	68	7.4
Adult Other ³ Perinatal/other pediatric ⁴	5	0.5 0.0
No risk identified or reported (NIR/NRR)	0	0.0
No risk identified of reported (Miny Mnn)	1	0.1

^{*} Percentages may not add up to 100% due to rounding 1. Deceased persons described in this table include those with a primary cause of death that is attributed to the underlying HIV infection or another reason (e.g. car accident, COVID-19).

2. Heterosexual contact: Defined as sexual contact with someone of the opposite sex with known risk such as injection drug use, bisexual male (applies to females only), person with hemophilia/coagulation disorder, transfusion recipient with HIV documentation, and or person with AIDS or documented HIV. 2. Includes perinatal exposure current age ≥ 13; hemophilia, blood transfusion. 3. Perinatal/other pediatric: cases<13 born to a mother who is HIV-positive, and cases <13 with missing risk. 4. Adjusted for missing risk using multiple imputation methods. Adjusted subtotals may be different from unadjusted subtotals due to rounding.

DISTRIBUTION OF GENERAL POPULATION BY RACE/ETHNICITY

TABLE 31. DISTRIBUTION OF THE GENERAL POPULATION BY RACE/ETHNICITY, GEORGIA, 2022

	Population	
	N	%*
Total	10,912,876	100.0%
Race/Ethnicity		
White, non-Hispanic	5,500,388	50.4%
Black, non-Hispanic	3,502,283	32.1%
Hispanic/Latino, Any Race	1,140,548	10.5%
Asian, Non-Hispanic	510,018	4.7%
American Indian /Alaskan Native, Non-Hispanic	25,046	0.2%
Native Hawaiian/Pacific Islander, Non-Hispanic	7,892	0.1%

^{*} Percentages may not add up to 100% due to rounding and because not all race/ethnicity groups are represented in the table. Data source: Georgia Online Analytical Statistical Information System

(https://oasis.state.ga.us/oasis/webquery/qryPopulation.aspx)

SUPPLEMENTARY INFORMATION

ADDITIONAL DATA ON HIV IN GEORGIA

- Georgia Department of Public Health HIV Epidemiology Section's Main Website:
 https://dph.georgia.gov/epidemiology/georgias-hivaids-epidemiology-section
 - Prior year HIV Surveillance Summary Reports are available under "HIV Case Surveillance Data Archive": https://dph.georgia.gov/epidemiology/georgias-hivaids-epidemiology-section/hivaids-case-surveillance
 - Other resources available include data on care continuum measures, trends overtime, fact sheets, special reports, and presentations: https://dph.georgia.gov/epidemiology/georgias-hivaidsepidemiology-section/hivaids-case-surveillance
- Centers for Disease Control and Prevention, Division of HIV Prevention: https://www.cdc.gov/hiv/default.html
- AIDSVu: https://aidsvu.org/

REPORTING

All health care providers diagnosing and/or providing care to a patient with HIV are required by Georgia law (O.C.G.A. §31-12-1) to report HIV infection using the HIV/AIDS Case Report Form.

Case report forms should be completed within seven (7) days of diagnosing a patient with HIV and/or AIDS or within seven (7) days of assuming care of an HIV positive patient who is new to the provider, regardless of whether the patient has previously received care elsewhere.

Adult and Pediatric case report forms are available at https://dph.georgia.gov/epidemiology/georgias-hivaids-epidemiology-section/hivaids-case-reporting

For more questions on HIV case reporting in Georgia please contact the HIV Surveillance Coordinator at 1-800-827-9769 (no faxing permitted). eFax: 404-506-9297

REQUESTING DATA

To request data, please visit http://dph.georgia.gov/phip-data-request to create a PHIP data request account and login.

